Review

**Pneumocystis Pneumonia in Solid-Organ Transplant Recipients**

Xavier Iriart 1,2,3,4,*, Marine Le Bouar 1,2,3,4, Nassim Kamar 2,4,5,† and Antoine Berry 1,2,3,4,†,*

1 Department of Parasitology-Mycology, Centre Hospitalier Universitaire de Toulouse, Hôpital Purpan, Institut Fédératif de biologie (IFB), 330 avenue de Grande Bretagne, TSA 40031, Toulouse 31059, France; E-Mail: lebouarmarine@gmail.com
2 INSERM U1043, Toulouse F-31300, France
3 CNRS UMR5282, Toulouse F-31300, France
4 Université de Toulouse, UPS, Centre de Physiopathologie de Toulouse Purpan (CPTP), Toulouse F-31300, France
5 Department of Nephrology and Organ Transplantation, CHU Rangueil, TSA 50032, Toulouse 31059, France; E-Mail: kamar.n@chu-toulouse.fr

† These authors contributed equally to this work.

* Authors to whom correspondence should be addressed; E-Mails: iriart.x@chu-toulouse.fr (X.I.); berry.a@chu-toulouse.fr (A.B.); Tel.: +335-6769-0499 (X.I.); +335-6769-0462 (A.B.).

Academic Editor: Shmuel Shoham

Received: 17 June 2015 / Accepted: 2 September 2015 / Published: 28 September 2015

**Abstract:** *Pneumocystis* pneumonia (PCP) is well known and described in AIDS patients. Due to the increasing use of cytotoxic and immunosuppressive therapies, the incidence of this infection has dramatically increased in the last years in patients with other predisposing immunodeiciencies and remains an important cause of morbidity and mortality in solid-organ transplant (SOT) recipients. PCP in HIV-negative patients, such as SOT patients, harbors some specificity compared to AIDS patients, which could change the medical management of these patients. This article summarizes the current knowledge on the epidemiology, risk factors, clinical manifestations, diagnoses, prevention, and treatment of *Pneumocystis* pneumonia in solid-organ transplant recipients, with a particular focus on the changes caused by the use of post-transplantation prophylaxis.

**Keywords:** *Pneumocystis jirovecii; Pneumocystis* pneumonia; transplantation; solid-organ transplant recipients
1. Introduction

*Pneumocystis jirovecii* is a ubiquitous and opportunistic fungus that is localized in the alveoli of human lungs and causes pneumonia. *Pneumocystis* pneumonia (PCP) remains a frequent cause of infection among immunocompromised patients [1,2].

*P. jirovecii* specifically infects humans, and PCP is an anthroponosis where humans are the only reservoir [3]. Rodent models and human observations have demonstrated inter-individual airborne transmission of PCP [3,4]. Recent data suggest that the cystic forms (but not the trophic forms) are responsible for transmission [5,6]. Transmission can occur from patients with PCP but also from asymptomatic hosts that can be transiently infected with *Pneumocystis* (colonization) [7–9]. Several data suggest that PCP is not a result of reactivation of a quiescent stage, such as cerebral toxoplasmosis, but rather is caused by direct infections or reinfections [10].

PCP was principally observed in HIV-positive patients in the 1990s [11] and is now well known and described in this population. Nevertheless, its incidence has dramatically increased over the last 15 years in patients with other predisposing immunodeficiencies [12–15], particularly transplant recipients [2,16–18]. Because of this emergence, it is necessary to know the specificity of PCP in other immunocompromised HIV-negative patients. Indeed, comparative studies on *P. jirovecii*-infected patients with AIDS, or with other immunodeficient conditions including transplantation, have shown substantial specificities in the patients’ demographics, and their biological and clinical presentations, outcomes, and mortality rates [19,20]. The objective of this review is not to develop official recommendations or to replace expert consensus, but to summarize the current knowledge on the epidemiology, risk factors, clinical manifestations, diagnoses, prevention, and treatment of *Pneumocystis* pneumonia in solid-organ transplant (SOT) recipients, taking into account the specificities of the medical management of these patients.

2. Epidemiology of SOT Recipients

2.1. Incidence

Since the 2000s, the ratio of *Pneumocystis* pneumonia in immunocompromised HIV-negative patients has increased rapidly [12–14,21]. Today, these patients represent the majority of PCP cases and underlying conditions include hematological malignancies, tumoral pathologies, hematopoietic stem cell transplantation, autoimmune or chronic inflammatory diseases, and solid-organ transplantation [22].

In more recent studies, SOT recipients represent ~30% of HIV-negative immunocompromised patients. Cases are mainly in kidney-transplant recipients because this is the main type of transplantation [22]. The most recent studies report that *Pneumocystis* infects 0.3%–2.6% of SOT recipients [23–27] whereas historic attack rates of PCP after solid-organ transplantation, defined as the biostatistical measure of frequency of morbidity in an at-risk population, were ~5%–15% [16,28,29]. This decrease over time is probably because of the use of primary and prolonged prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX) today, as well as the use of modern immunosuppressive regimens [23].

The rate of PCP infection depends on the type of transplantation and is greater in heart-, lung-, and combined heart–lung transplantation than in kidney- or liver-transplant recipients, regardless of
whether they do or do not receive prophylaxis (Table 1). This is probably because thoracic transplants recipients receive more intensive immunosuppressive therapies [30].

**Table 1.** Attack rate of *Pneumocystis* pneumonia (PCP) in transplant recipients. Adapted from Rodriguez *et al.* [31].

| Organ Transplanted | Patients not Receiving Prophylaxis | Patients Receiving Prophylaxis * |
|--------------------|-----------------------------------|----------------------------------|
| Kidney             | 0.6–14 [30,32–34]                 | 0.4–2.2 a [16,24,25,27]          |
| Liver              | 3–11 [35–37]                     | 1.1–3.7 [16,25,27,38]            |
| Heart              | 2–41 [30,39–41]                  | 2–5.1 [16,27]                    |
| Heart–lung/lung    | 6.5–43 [39,42]                   | 5–5.8 [16,25]                    |

* Early post-transplantation prophylaxis given for 6 months to 1 year. a Data from the study from Radisic *et al.* [43] has not been included (Attack rate: 5.4%) because of a preponderance of patients that had failed primary TMP-SMX prophylaxis.

In studies in which early post-transplantation prophylaxis against PCP was used, the attack rates of infection were drastically decreased for all types of transplantation (Table 1). The reported incidence rates of infection are 22 per 1000 patient-years for lung-transplant recipients, 0.14–7.3 per 1000 patient-years for heart-transplant recipients, 0.4–2.7 per 1000 patient-years for kidney-transplant recipients, and 0.2–10 per 1000 patient-years for liver-transplant recipients [16,27,44].

2.2. The High-Risk Period for PCP Development

The period of highest risk when PCP develops changes according to the use of early prophylaxis with TMP-SMX. Before the generalized use of prophylaxis, the highest risk period for developing PCP was the first six months after transplantation [33,45–50], particularly between the second and sixth month post-transplantation, and during periods of intensified immunosuppression [26].

Since the establishment of routine TMP-SMX (or an alternative agent such as dapsone or atovaquone) prophylaxis, PCP within the first year post-transplant, has been virtually eliminated [13,51–53] and, today, this infection seems to occur mainly after the first year (Figure 1). Currently, the second year post-transplantation has a greater risk period of PCP with a high incidence in patients who have benefited from TMP-SMX prophylaxis within the first year [24,27]. However, the global incidence of SOT patients that develop PCP during the second year post-transplant is relatively low (<0.6%) [27].

Early prophylaxis seems to greatly reduce the risk of PCP during the first year but not within the second year. However, this is not a rebound effect, as second-year post-prophylaxis rates are comparable to second-year rates in centers that do not prescribe post-transplantation prophylaxis [26]. After the second year, the risk is lower and then remains so, but some risk persists for long after transplantation [24,27], possibly for the patient’s lifetime.
Figure 1. Risk of *Pneumocystis* pneumonia (PCP) at post-transplantation over time in patients that benefited from early prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX). Adapted from Iriart *et al.* [27]. The two dotted lines (1 and 2 years) delimit three different periods in the occurrence of the disease after the transplantation.

2.3. Seasonal Incidence

General data on a possible seasonal incidence of PCP are relatively discordant according to the studies. In two studies from the UK and Spain, a positive correlation was found between PCP incidence and colder months [54–56] but a higher incidence of PCP was found to be associated with the summer period in a recent study from Germany [57]. No seasonal variation of mortality due to PCP in HIV-infected individuals was observed in the Miller *et al.* study from the UK [58]. These discordances can be explained by the existence of other factors linked to climate, as, for example, human behavior, that outweigh the influence of single climatic factors. A systematic review of 10 studies reporting outbreaks of PCP in kidney transplant recipients shows no determining influence of climatic conditions [59]. The timing of peak incidence occurred during winter in four studies, during spring in one and in summer or early fall in five out of 10 studies, and no association between the time of diagnosis of the index case and any month or season [59].

2.4. Nosocomial Outbreaks

In transplant units, cases of PCP are often isolated but nosocomial outbreaks have been described, particularly for kidney-transplant recipients [48,60–65]. This is probably related to the high number of immunocompromised kidney SOT patients worldwide, plus their need for regular follow-up visits within hospital settings, involving potential inter-individual transmissions between receptive patients, colonized medical workers or colonized patients [66]. Nevertheless, a common source of exposure linked within transplant units cannot be excluded, as suggested by studies that detected *Pneumocystis* DNA in air samples from hospital-patient care rooms [67,68].
3. Risk Factors

Some risk factors for PCP are common, with these classically observed in all types of patients whereas other risk factors are specific to SOT recipients.

3.1. Immunosuppressive Regimens

The main risk factors for contracting PCP in SOT recipients are associated with immunosuppressant therapies. As observed during acute rejection episodes, the relative risk of PCP increases with the number of rejection treatment [26,43,50]; however, the contribution of individual immunosuppressants remains uncertain [69]. In several studies, the occurrence of PCP in SOT recipients has been directly linked to specific immunosuppressive regimens [33,70–72]. One of the more comprehensive studies on this topic was reported in the United States Renal Data System (USRDS) analyses, which included 142 patients with PCP and 32,615 controls [71]. Table 2 reports these results.

Table 2. Immunosuppressive regimens reported within the United States Renal Data System analyses. A total of 32,757 medicare primary adult recipients of a kidney transplant between 2000 and 2004. Adapted from Neff et al. [71].

| N     | PCP (%) | Controls (%) | p-Value; OR (95%CI) |
|-------|---------|--------------|---------------------|
| 142   | 32,615  | -            |                     |

**Induction Therapy**

|                    | PCP (%) | Controls (%) | p-Value | OR (95%CI) |
|--------------------|---------|--------------|---------|------------|
| None               | 33 (23.2) | 5922 (18.2) | 0.12    |            |
| Thymoglobulin      | 29 (20.4) | 7783 (23.9) | 0.37    |            |
| IL-2 receptor antibody | 52 (36.6) | 12,389 (38.0) | 0.79    |            |
| Alemtuzumab        | 2 (1.4) | 476 (1.5) | 0.96    |            |

**Discharge Immunosuppression**

|                    | PCP (%) | Controls (%) | p-Value; OR (95%CI) |
|--------------------|---------|--------------|---------------------|
| Tacrolimus         | 79 (55.6) | 18,878 (57.9) | 0.61               |            |
| Cyclosporine (Neoral) | 48 (33.8) | 8755 (26.8) | 0.07               |            |
| Mycophenolate mofetil | 96 (67.6) | 25,415 (77.9) | 0.004              |            |
| Mycophenolate sodium | 0 (0) | 89 (0.3) | 0.68               |            |
| Azathioprine       | 7 (4.9) | 900 (2.8) | 0.12               |            |
| Sirolimus          | 41 (28.9) | 4857 (14.9) | <0.001             |            |
| Steroids           | 124 (87.3) | 28,916 (88.7) | 0.61               |            |

**Discharge Immunosuppression by Combinations**

|                    | PCP (%) | Controls (%) | p-Value; OR (95%CI) |
|--------------------|---------|--------------|---------------------|
| Tacrolimus and mycophenolate mofetil | 39 (27.5) | 14,715 (45.1) | Reference 1.0       |            |
| Tacrolimus and sirolimus        | 21 (14.8) | 1861 (5.7) | <0.001; 4.26 (2.50–7.25) |            |
| Cyclosporine (Neoral) and mycophenolate mofetil | 39 (27.5) | 6762 (20.7) | 0.001; 2.18 (1.40–3.40) |            |
| Sirolimus and mycophenolate mofetil | 12 (8.5) | 1544 (4.7) | 0.001; 2.90 (1.53–5.61) |            |
| All other combinations         | 31 (21.8) | 7733 (23.7) | 0.09; 1.51(0.94–2.42) |            |

*Bold indicates a p-value <0.05.*

Nevertheless, data on the risk factors associated with immunosuppressive regimens are often contradictory due to the lack of homogeneity in drug dosages, the types of combinations used, the periods and sizes of the studies, and the use of PCP prophylaxis.
3.1.1. Polyclonal/Monoclonal Antibodies

Induction therapies, particularly those that include polyclonal antibodies that deplete the lymphocyte pool, including CD4+ lymphocytes [73–75], are linked to a high risk of PCP during the first six months post-transplantation [76]. This risk of PCP is shared with populations with connective tissue diseases [15], who have also exposure to biological agents that may predispose to PCP infection, including TNF, CD20, or CD52 depleting therapies [77]. Nevertheless, no risk factors linked with induction therapies were identified in the USRDS analyses in SOT patients [71] (Table 2). Monoclonal antibodies, such as alemtuzumab or rituximab, used as induction therapies or to treat acute rejection in solid-organ transplantation, have been shown to confer a high risk of PCP in patients with hematological malignancies [77,78]. Few data are available concerning the risk of PCP associated with the use of IL2-receptor antagonists (IL2-RA). In Eitner et al.’s study, a lower rate of PCP infection was observed in patients treated with an IL2-RA [79]. To explain this finding, the authors hypothesized that either this drug had a direct action on *Pneumocystis* or IL-2RA acted indirectly by reducing the risk of rejection episodes and thereby reducing the need for immunosuppressive-associated treatments [79].

3.1.2. Corticosteroids

Corticosteroids interfere with many pathways within the immune system [80], and they decrease the number and function of different cell populations, such as monocytes and macrophages [81,82], as well as peripheral blood CD4+ lymphocytes [83]. Corticosteroids have been clearly associated with a significant risk for PCP in non-HIV patients [84,85]. Although this corticosteroid-linked risk was not identified in the USRDS analyses [71] (Table 2), De Castro et al. showed that a longer duration of high-dose steroid therapy (>0.25 mg/kg per day) was associated with a higher risk of PCP in recipients of a kidney transplant (OR 1.6 per month, 95%CI: 1.04–2.93, \( p = 0.005 \)) [86].

3.1.3. Mycophenolate Acid

Mycophenolate acid (MPA) inhibits an enzyme implicated in purine synthesis, which is linked with the proliferation of B and T lymphocytes [87]. The first *in vitro* animal models indicated that MPA had an anti-*Pneumocystis* effect [88]. Furthermore, three clinical trials that evaluated MPA reported no cases of PCP in those that received MPA compared to 1.2%–2.4% of those that did not [89–91]. The USRDS data are consistent in showing that MPA was more frequently given to uninfected controls (Table 2) [71]. However, even though some authors have raised the question of the necessity of giving PCP prophylaxis when MPA is used [92], many cases of PCP have been reported in patients receiving MPA [23,71,93] and two recent retrospective case-control studies from Eitner et al. and Rostved et al. report an increased number of cases of PCP in MPA-treated patients. These data suggest that MPA alone or in combination did not confer any effective protection but, rather, was associated with an increased incidence of PCP [79,94].
3.1.4. Calcineurin Inhibitors

Calcineurin inhibitors, including cyclosporine and tacrolimus, reduce the proliferation and differentiation of T lymphocytes by preventing interleukin-2 (IL-2) production. A first case series and experimental studies suggest that cyclosporine increases the risk of PCP in contrast to azathioprine or MPA [72,88,95]. For example, Hardy et al. observed an increase in the incidence of PCP from 3% to 9% when cyclosporine replaced azathioprine in kidney-transplant recipients at their institution [45]. Nevertheless, the retrospective study of Luft et al. showed a higher incidence of PCP among kidney-transplant recipients receiving a tacrolimus-based regimen compared to one based on cyclosporine [33].

More recently, the USRDS analyses did not identify tacrolimus as a risk factor for PCP \( (p = 0.61) \), whereas the use of cyclosporine was associated with a non-significant trend towards developing PCP \( (p = 0.07) \) [71] (Table 2). Conversely, in the case-control study of De Castro et al., SOT recipients that contracted PCP were less likely to have received calcineurin inhibitors compared to those without PCP (OR 0.09, 95%CI 0–0.67, \( p = 0.004 \)) [86]. These results were confirmed in a recent study by Iriart et al., which also identified tacrolimus as a protective factor [27].

3.1.5. mTOR Inhibitors

Sirolimus inhibits the response to interleukin-2, thus blocking the activation of T and B cells [77]. Initial studies on sirolimus also report high levels of PCP [70,96]. Two recent case-controls studies have confirmed an association between the use of sirolimus and the development of PCP: i.e., De Castro et al. (OR 7.7, 95%CI 1.2–∞, \( p = 0.02 \)) [86] and Neff et al. (\( p < 0.001 \)) [71] (Table 2), as well as a study on pediatric recipients with an intestinal transplant [97].

3.1.6. Combinations

In the USRDS review, maintenance immunosuppression regimens containing the combination of tacrolimus plus sirolimus, cyclosporin plus mycophenolate mofetil, and sirolimus plus mycophenolate mofetil were found to be significant risk factors for contracting a Pneumocystis infection [71] (Table 2).

3.2. Acute Rejection

The risk of PCP is also increased during phases when immunosuppression is enhanced, such as during an acute rejection. Five case-control studies identified a relationship between graft rejection and the risk of PCP [26,43,50,79,86] (Table 3). Even if the number of rejection episodes appeared to be a risk factor in Radisic et al.’s study [43], the number of treatments associated with acute-rejection episodes seemed to be the main parameter that accounted for this risk, irrespective of the drugs used.
Table 3. Identification of graft rejection as a risk factor for *Pneumocystis* pneumonia (PCP) in case-control studies.

| Study           | Prophylaxis | PCP Patients, n | Timing of Rejection (Post-Transplantation-Day) | Evaluated Criteria                  | Statistical Analysis | OR (95%CI)  |
|-----------------|-------------|-----------------|-----------------------------------------------|-------------------------------------|----------------------|-------------|
| Arend et al.    | No          | 15              | 1st episode: 20                               | No. of rejection treatment          | Trend in relative risk | 9.5 (1.6–56.4) |
| 1996 [50]       |             |                 | 2nd episode: 34                               | (p = 0.002)                         |                      |             |
|                 |             |                 | 3rd episode: 57                               |                                     |                      |             |
| Radisic et al.  | 1 year      | 17              | 1st episode: 8                                | Rejection episode                    | Univ (p = 0.02)      | NA          |
| 2003 [43]       |             |                 | 2nd episode: 49                               |                                     |                      |             |
|                 |             |                 | 3rd episode: 62                               |                                     |                      |             |
| De Castro et al.| 3 months    | 11              | NA                                            | Rejection episode                    | Univ (p = 0.002)      | 14.4 (2.1-inf) |
| 2010 [86]       |             |                 |                                               |                                     | Multiv (p = 0.017)   | 8.7 (1.2-inf) |
| Eitner et al.   | No          | 60              | NA                                            | Biopsy-proven acute rejection episode| Univ (p = 0.0029)    | NA          |
| 2011 [79]       |             |                 |                                               |                                     |                      |             |
| De Boer et al.  | No          | 50              | 1st episode: 16                               | Rejection treatment                 | Multiv (p = 0.002)   | 5.8 (1.9–17.5) |
| 2011 [26]       |             |                 | Last episode: 48                              |                                     |                      |             |

NA: not available; OR (95%CI): odds ratio (95% confidence interval); Univ: univariate analysis; Multiv: multivariate analysis.
Because patients with a graft rejection receive a heavier burden of immunosuppression, they are more susceptible to PCP and other opportunistic infections. The use of polyclonal/monoclonal anti-lymphocyte antibodies in this context or patients who have a steroid-resistant allograft rejection seem to have additional risk factors for PCP (OR: 7.2 (95%CI: 1.3–49.3) and 4.3 (95%CI: 1.04–18.9), respectively) [43]. Because of the high number of kidney transplantations, these data mainly concern this population of patients but the risk of graft rejection has been also identified in adult liver-transplant recipients [38]. Except for two studies in which prophylaxis was either initiated for a short duration (three months) [86] or was associated with a high rate of failure for an undetermined reason [43], this risk was mainly identified in studies that included patients who had not received primary PCP prophylaxis (Table 3). However, in recent studies where patients benefited from six months of PCP prophylaxis, the risk factors associated with graft rejection were not confirmed [27,65]: perhaps graft rejection happened generally during the period covered by primary post-transplantation TMP-SMX prophylaxis.

3.3. Comorbidity Conditions and Co-Infections

Comorbidity conditions, such as underlying pulmonary diseases, transplant dysfunction [65], cancer, or transplant-donor factors [71], are more frequent in SOT recipient who develop PCP. Concomitant infections, such as tuberculosis, bacterial pneumonia, and hepatitis C infection, have also been associated with a risk of PCP [43], but cytomegalovirus (CMV) infection seems to be the co-infection that plays the most significant role in affects PCP SOT recipients.

Several case-control studies have identified CMV as a clear risk factor for PCP in SOT patients [26,43,50,65,71,98], regardless of whether these patients benefited from prophylaxis for PCP or not (Table 4). Except for the Arend et al.’s study [50], the CMV donor’s/recipient’s serostatus at transplantation was not significantly associated with PCP, even if the donor was CMV-positive and the recipient was CMV-negative [26,27,71].

The risk for PCP is mainly associated with patients who have had a CMV infection or CMV disease after transplantation [26,27,43,50,71,98]. Table 4 shows that 20%–53% of SOT recipients with PCP had a CMV infection compared to 0.6%–24% of those who did not develop PCP.

These CMV infections were mainly caused by CMV reactivation rather than a primary CMV infection [27]. However, it is unclear whether CMV infections simply reflect the degree of immunosuppression [16,33,45,47,48] or if CMV can directly increase the risk of PCP [50]. Nevertheless, it is noteworthy that cytomegalovirus has an immunosuppressive effect and causes marked impairment in cell-mediated immunity [99], which could reinforce the idea that CMV infection is a causal risk factor for PCP, independent of immunosuppression level [50].
Table 4. Identification of cytomegalovirus (CMV) as a risk factor for *Pneumocystis* pneumonia (PCP) in case-control studies.

| Study               | Prophylaxis | PCP Patients, *n* | Evaluated Criteria | CMV in PCP Cases, % | CMV in Controls, % | Statistical Analyses | OR (95%CI)     |
|---------------------|-------------|-------------------|--------------------|---------------------|---------------------|----------------------|-----------------|
| Arend *et al.* 1996 [50] | No          | 15                | CMV infection      | 53.3%               | 18.8%               | Univ (*p* < 0.05) Multiv (*p* < 0.05) | 5.0 (1.6–15.8) |
| Radisic *et al.* 2003 [43] | 1 year      | 17                | CMV infection      | 52.9%               | 23.5%               | Univ (*p* = 0.036) | NA             |
| Neff *et al.* 2009 [71] | NA          | 142               | CMV disease        | 20.4%               | 8.8%                | Univ (*p* < 0.001) Multiv: NS | -              |
| de Boer *et al.* 2011 [26] | No          | 50                | CMV infection      | NA                  | NA                  | Univ (*p* = 0.02) Multiv (*p* = 0.05) | 2.7 (1.2–6.2) |
| Phipps *et al.* 2011 [65] | 6 months    | 14                | CMV disease        | 35.7%               | 0.6%                | Univ (*p* < 0.001) Multiv (*p* < 0.001) | 65.9 (7.9–550) |
| Pliquett *et al.* 2012 [98] | No          | 29                | CMV infection and disease | 41.4%               | 3.4%                | Univ (*p* < 0.05) | NA             |
| Rostved *et al.* 2013 [94] | No *a*       | 16                | CMV infection      | 31% *b*             | 6% *b*             | Univ (*p* = 0.03) *b*  | NA             |
|                     |             |                   |                    | 29% *c*             | 0% *c*             | Univ (*p* = 0.009) *c* |                |
| Iriart *et al.* 2015 [27] | 6 months    | 33                | CMV infection      | 51.5%               | 18.2%               | Univ (*p* < 0.001) Multiv (*p* = 0.002) | 5.2 (1.8–14.7) |

NA: not available; NS: not significant; OR (95%CI): odds ratio (95% confidence interval); Univ: univariate analysis; Multiv: multivariate analysis. *a* Initiated at the end of the outbreak; *b* kidney-transplant recipient; *c* liver-transplant recipient.
3.4. Blood Parameters

Some parameters that reflect the host-immune response are associated with a higher risk of PCP. The number and functional capacity of lymphocytes are especially important in a host’s defenses against *Pneumocystis* [100]. A decreased lymphocyte count, particularly of CD4+ T-cells, has been clearly linked to PCP in HIV-positive patients [101]. Even though blood CD4+ T-cell levels seem to less accurately reflect the risk of PCP in HIV-negative patients compared to alveolar CD4+ T lymphocyte counts [20], CD4+ T-cell lymphopenia has been also associated with PCP in HIV-negative patients [102], particularly in hematopoietic stem cell transplantation recipients [103], in solid-tumor patients receiving chemotherapy [84], in those with an autoimmune disease, and those with a hematological malignancy [104].

Recently, three studies have demonstrated that CD4+ T-cell lymphopenia or a lower total lymphocyte count are also risk factors for PCP in transplant recipients [27,29,86], although with some differences in threshold levels (750/µL and 500/µL in Iriart et al.’s and De Castro et al.’s studies, respectively [27,86]) and the decay kinetics of lymphocytes. Indeed, Struijk et al. reported that a significant decrease in lymphocytes occurred for about two years before PCP developed [29], whereas this decrease was only significant at ~50 days before PCP was evident in Iriart et al.’s study [27].

However, overall, these data suggest that lymphocyte counts may help guide an indication for chemoprophylaxis in these patients. Moreover, a lower total gamma globulin concentration in SOT patients with PCP was identified as risk factor in one case-control study [27], suggesting an alteration of the humoral immunity response, which plays a significant role against *Pneumocystis* [105]. In addition, prolonged neutropenia is a potential risk factor for PCP in transplant recipients, as observed in patients with a hematological malignancy [32].

3.5. Risk Period for PCP in SOT Recipients

As mentioned above, TMP-SMX prophylaxis influences when the highest risk of PCP occurs. Before the use of prophylaxis, this period was the first six months after transplantation [33,45–50], during the period of intensified immunosuppression [26]. Today, now that primary prophylaxis is usually used, PCP is rare within the first year [13,51–53], but the second year post-transplantation is now a new high-risk period for PCP [24,27]. After the second year, the risk is lower, but then persists at a relatively constant level, probably for the entire lifetime of the SOT recipient [24,27].

3.6. Nosocomial Risk

Failures of prophylaxis can also be linked to outbreaks of PCP [98,106], which are particularly frequent in renal-transplant units [60–63,106,107], although close contact with healthcare-associated clusters of PCP infection may also constitute a nosocomial risk factor for SOT recipients.

3.7. Characteristics of SOT Recipients

Age appears to be an independent risk factor for PCP, both in studies that have focused on HIV-positive or -negative patients with PCP, such as SOT recipients [26,27]. Risks seem to be increased for SOT recipients aged >55 years (OR 2.7, 95%CI 1.3–5.9) and the risk increases with
age [26,27]. Female gender was associated with a higher incidence of PCP in one study [71]. The risk of PCP is higher in heart-, lung-, and combined heart–lung transplant recipients than in kidney- or liver-transplant recipients regardless of them receiving or not receiving prophylaxis (Table 1): this is probably due to the more intense immunosuppressive therapy given to the first patients [30].

The colonization of *Pneumocystis* also plays a role in the transmission of this fungus. This has been observed in healthy individuals but also in patients at risk for PCP. Although no study on SOT patients has demonstrated that colonization is an independent risk factor for PCP, several data suggest that colonization can precede infection [93].

### 3.8. Strategies to Target Patients at Risk for PCP

In two studies, the authors proposed strategies to target SOT recipients at high risk for PCP using risk factors commonly identified in this population [26,27]. The first study selected the most efficacious prophylactic strategies given within the first two years post-transplantation in patients who had not benefited from a prophylaxis [26]. The second study focused on patients with a high risk of PCP after the first year, and on SOT recipients who had benefited from initial TMP-SMX prophylaxis [27]. When age, the date of transplantation, any rejection episodes, lymphocyte counts, and detectable CMV viremia were considered in these scenarios, the prescription for PCP chemoprophylaxis according these criteria would result in a lower incidence of PCP and greater avoidance of TMP-SMX toxicity [108].

### 4. Clinical Manifestations and Outcomes

#### 4.1. Clinical Manifestations

Whereas HIV-positive patients present with a subacute course and progressive deterioration of respiratory status (symptom duration: 25–28 days), symptomatic progression of PCP is, in general, more acute in HIV-negative patients (symptom duration: 5–6 days) [109,110]. In HIV-negative patients, common PCP symptoms, such as fever [111], are sometimes lacking because immunosuppressive agents have suppressed the clinical findings [76]. In the setting of transplantation, symptoms often develop over the course of a few days, although evolution over 1–2 weeks can also occur [111].

Pneumonia is the primary manifestation of a *P. jirovecii* infection. Common, but non-specific associated symptoms are fever, dyspnea, and a dry cough. Respiratory involvement is usually more severe in HIV-negative patients, with low arterial-oxygen tension and more frequent acute respiratory failure [109,110,112]. Table 5 reports the frequency of clinical presentations of PCP among kidney-transplant recipients in recent studies. Examinations of the lungs are often normal, even if there is hypoxemic presentation, but discrete crackles may be present [113]. A pneumothorax, often associated with acute dyspnea and pleuritic chest pain, may be observed, but is rare [114].
Table 5. Clinical presentations, radiological findings, and outcomes from *Pneumocystis* pneumonia (PCP) among kidney-transplant recipients in studies published after 2010.

| Clinical Criteria                  | Reference  | Frequency (%) |
|-----------------------------------|------------|---------------|
| **Clinical Presentation**         |            |               |
| Cough                             | [29,86]    | 78%–100%      |
| Fever                             | [29,86]    | 67%–100%      |
| Dyspnea                           | [29,86]    | 73%–100%      |
| Acute respiratory failure         | [24,29,86] | 22%–69%       |
| **Radiological Findings**         |            |               |
| Bilateral interstitial infiltrates | [29,86]    | 89%–100%      |
| Unilateral infiltrate             | [29]       | 11%           |
| **Outcome**                       |            |               |
| ICU admission                      | [26,65,79] | 8%–71%        |
| Mechanical ventilation            | [26,65,79] | 8%–71%        |
| Death                             | [24,26,29,65,79,86,94] | 0%–27%       |
| Death (total from all the studies) | [24,26,29,65,79,86,94] | 25/173 (14%) |

ICU: intensive-care unit.

4.2. Outcomes

In most studies, the outcome from PCP is generally described as being poorer in HIV-negative than in HIV-positive patients [21,22]. Hypoxemia has been reported to be more severe in HIV-negative than in HIV-positive patients. HIV-negative patients required higher oxygen-flow rates, more intensive-care admissions (50% vs. 35% for HIV-positive patients), and a greater need for invasive ventilation (30.5% vs. 11% for HIV-positive patients) [22]. Recent data concerning the outcomes of kidney-transplant recipients with PCP are presented in Table 5 and show there is high variability in the numbers of patients that are admitted into intensive-care units and need mechanical ventilation (8%–71%) [26,65,79].

PCP may also, in some cases, participate in graft loss, particularly in kidney-transplant recipients [71]. Hospital deaths are currently described as being higher in HIV-negative patients (27% vs. 4% for HIV-positive patients) [22]. Nevertheless, some reports have observed similar rates of mortality between these two populations, which may be explained by the increased use of adjunctive glucocorticoids in HIV-negative patients [18,51,115].

Mortality in the HIV-negative population varies according to the cause of the immunodeficiency [22]. Of interest, death rates seem to be lower for SOT recipients than for patients with other types of immunosuppression [22]. SOT has been identified as an independent variable associated with a lower death rate (OR 0.08, 95%CI: 0.02–0.31), and comparable to that of AIDS (OR 0.33, 95%CI: 0.12–0.92) [22].

The death rate among kidney-transplant recipients seems to have drastically decreased from about 50% before 1990 [47,116–118] to about 14% today (Table 5) [24,26,29,65,79,86,94]. Few recent data are available for other organ-transplant recipients, but death rates are about 7%–50% for liver- [25,38,94], 33% for lung- [25], and 5.5%–11% for heart-transplant [119,120] recipients.
A delayed diagnosis, resulting in a delay in the initiation of an adapted PCP therapy, can participate in a poor outcome, as the time from admission to initiation of PCP treatment is an independent predictor of mortality (OR 1.11/additional day, 95%CI: 1.04–1.18) [22]. Being older, needing oxygen or invasive mechanical ventilation on admission indicate a poor prognosis. A World Health Organization (WHO) performance status over 2, a lack of control of the underlying disease, a high temperature, hypoalbuminemia, shock, and clinical worsening by day 5 are also associated with increased mortality [121,122]. Pulmonary co-infections with herpes simplex virus or CMV and a high neutrophil count in a broncho-alveolar lavage (BAL) are also linked with more severe hypoxemia and higher mortality rates [123,124].

5. Microbiological and Radiological Diagnoses

5.1. Radiological Diagnosis

Radiographic imaging of HIV-negative patients is similar to that for HIV-positive patients with PCP. A typical radiographic feature of PCP is the presence of bilateral, symmetric, diffuse, reticular, or granular opacities [125], but these chest-radiographic images are non-specific and may be normal at diagnosis [126]. The interstitial infiltrates are mostly bilateral and are also frequently observed in SOT recipients (Table 5). These opacities are typically perihilar in mild presentations or diffuse in severe presentations. Typically, reticular and poorly defined ground-glass opacities progress to alveolar consolidation in 3–4 days [121].

High-resolution computed-tomography scans (HRCT) are more sensitive than chest radiography at detecting PCP [126]. HRCT can be indicated in HIV-negative patients with a normal chest radiograph [127]. HRCT may typically show ground-glass opacities, which predominate in the perihilar regions of lungs: however, these abnormalities are non-specific [128]. As their sensitivity and specificity are 100% and 89%, respectively, a normal HRCT may allow exclusion of PCP [129]. Thickened septal lines and areas of consolidation may be also present [130].

Pulmonary cysts occur in 3%–6% of non-HIV-patients with PCP and are associated with an increased risk of spontaneous pneumothorax [130]. Ground-glass opacities resolve completely after initiation of treatment in 97% of patients after a median period of 13 days [130]. Some differences in HRCT presentation exist according to HIV status, with a more rapid spread and a larger extent of ground-glass opacities, and a lower incidence of pulmonary cysts and a higher frequency of thickened septal lines described in HIV-negative patients than in AIDS patients with PCP [130].

5.2. Microbiological Diagnosis

There are important differences in the clinical presentation, outcomes and mortality of patients with PCP and with or without AIDS. These differences also concern the diagnosis in HIV-negative patients with PCP, including SOT recipients, who have a lower burden of \textit{P. jirovecii} than those with AIDS, which leads to difficulty in detecting the fungus [131].
5.2.1. Samples

Microbiological diagnosis of PCP is possible in a great variety of pulmonary specimens (Table 6). However, the most appropriate sample has to be selected by taking into account the best diagnostic sensitivity and the lower invasiveness of the sampling procedure. Due to the importance of minimal invasiveness and the development of sensitive methods to make a diagnosis, such as real-time PCR, transbronchial or an open-lung biopsy, are now rarely used in most centers and a diagnosis of PCP is preferentially obtained from a BAL fluid sample or induced sputum. Although BAL fluid remains the sample of choice, induced sputum is a rapid and cost-effective diagnostic procedure, and is less invasive than bronchoscopy [52,121]. At this time, the development of highly sensitive molecular diagnosis tools has allowed less invasive sampling of the upper respiratory tract, such as oral washing or aspiration [132,133]. New approaches, such as detection of the β-D-glucan antigen in blood samples, also helps facilitate in the diagnostic management of PCP [134].

Table 6. Numbers of *Pneumocystis* pneumonia (PCP) diagnosed with traditional diagnostic methods according to the type of samples. Adapted from Rodriguez et al. [31].

| Type of Sample                                      | Reference        | PCP Diagnosed (%) |
|-----------------------------------------------------|------------------|-------------------|
| Routine sputum                                       | [114,135]        | Poor              |
| Induced sputum                                       | [136,137]        | 30–55             |
| Bronchoalveolar lavage                              | [137,138]        | 80–95             |
| Bronchoalveolar lavage and transbronchial biopsy    | [137,139]        | >95               |
| Open-lung biopsy                                     | [140]            | >95               |

5.2.2. Traditional Diagnostic Methods

As *Pneumocystis* remains a non-cultivable microorganism, traditional diagnostic methods rely on microscopic observations of the pathogen in respiratory specimens. During infection, two life-cycle forms can be found: the asci (formerly named cysts) and the trophic form, with the latter being more dominant than the asci form in PCP [141]. Trophic forms can be detected with modified Papanicolaou, May-Grünwald Giemsa, Giemsa, or Gram-Weigert stains. *P. jirovecii* asci can be stained with Gomori methenamine silver, toluidine blue, cresyl echt violet, or calcofluor white [142]. An immunofluorescence assay with anti-*Pneumocystis* antibodies is commercially available: it provides the best specificity and sensitivity of the general stains [136] and some immunofluorescent monoclonal antibodies can reveal both trophic and asci forms. Before the development of PCR, this method represented the “gold standard” technique for the diagnosis of PCP.

Although microscopic methods are often sufficient to diagnose *P. jirovecii* in BAL fluids from AIDS patients, the sensitivity of these methods is often too low to diagnose PCP in non-HIV immunocompromised patients [124]. In SOT recipients, molecular diagnostic methods are required to avoid missing a *Pneumocystis* infection in this population.
5.2.3. Diagnoses with the Polymerase Chain Reaction

The use of the polymerase chain reaction (PCR) assays has improved the sensitivity of detecting *Pneumocystis*, particularly in non-HIV-patients. Numerous assays using various gene targets and different PCR-detection methods (single-step, nested, semi-nested, real-time PCR) have revealed PCR to be highly effective at diagnosing PCP in both HIV-positive and HIV-negative patients [77,143–147]. The high negative predictive value of this method, close to 100%, allows PCP to be excluded with a high probability and cotrimoxazole therapy can then be discontinued when PCR is negative [148].

Among the numerous gene targets evaluated in different studies (dihydropteroate synthase, dihydrofolate reductase, internal transcribed spacer regions of the rRNA gene, mitochondrial large subunit ribosomal RNA, 5S rRNA, b-tubulin, major surface glycoproteins, kex-1, cdc2 gene loci), sensitivity seems to be generally highest in assays directed at multicopy targets, such as the major surface glycoproteins (MSG) and the mitochondrial large subunit ribosomal RNA (mtLSU rRNA) genes [77].

Conventional PCR (nested or hemi-nested) has a higher sensitivity than traditional diagnostic methods, but suffers from several limitations. This test has low specificity, high false-positive rates, and low positive predictive values, and cannot differentiate PCP from asymptomatic *Pneumocystis* colonization. Moreover, the possibility of run-to-run contamination is high, limiting its utility in diagnostic practice [144,146,149]. Real-time quantitative PCR (qPCR) assay results have been developed to improve test specificity and semiquantitative results provided by these methods may help differentiation between PCP and *Pneumocystis* colonization [146,149].

Reported performances for PCP diagnoses have been excellent, particularly in assays directed at MSG and mtLSU rRNA genes (Table 7), with sensitivities from 93% to 100% and specificities higher than those observed for standard PCR (83%–100%). Other advantages of this method are the reduced turnaround times (<3 h) and the reduced possibility of run-to-run contamination [77]. Clinically relevant cut-off PCR values of fungal load have been proposed to discriminate between colonization and PCP entities. Nevertheless, as most studies concern non-commercial PCR kits, the extrapolation of a threshold from one technique to another is difficult [121]. In several studies, the number of DNA copies per tube or the number of trophic-form equivalents have been proposed to discriminate active pneumonia from colonization [150–152]. In other studies, cycle thresholds (Ct) of the qPCR assay have been used as a “cut-off” to distinguish between the two clinical entities [153,154]. As significant fluctuations in the amount of fungal DNA may occur, because of the variable amounts of saline used in the lavage procedure and/or the pre-analytic factors such as sample transport conditions [77], thresholds based on Ct seem to have sufficient precision to guide towards colonization or PCP. Nevertheless, clinical judgment and radiological presentation are essential to distinguish PCP from a simple colonization, and more so if the fungal burden is low.
Table 7. Major studies that have evaluated a diagnosis of *Pneumocystis* pneumonia (PCP) using real-time PCR directed at major surface glycoproteins (MSG) and mitochondrial large subunit (mtLSU) rRNA genes, in non-HIV immunocompromised patients. Adapted from Reid *et al.* [77].

| Study          | Target Gene | Specimen (No.) | No. PCP Episodes | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|----------------|-------------|----------------|------------------|-----------------|-----------------|---------|---------|
| Flori *et al.* [146] | mtLSU rRNA   | BAL (173)      | 11               | 100             | 87              | NA      | NA      |
| Dini *et al.* [155]   | mtLSU rRNA   | Respiratory tract (932) | 150          | 100             | 83 ^a           | 78.1 ^a | 100 ^a  |
| Hauser *et al.* [156] | mtLSU rRNA   | Respiratory tract (110) | 14            | 93              | 90–91           | 59–65   | 98–99   |
| Alanio *et al.* [152] | mtLSU rRNA   | BAL (163) | IS (115)         | 16              | 100             | 85.7    | 72.4 ^a | 100     |
| Flori *et al.* [146] | MSG          | BAL (173)      | 11               | 100             | 98.6            | 84.6 ^a | 100 ^a  |
| Alvarez-Martinez *et al.* [157] | MSG          | BAL, IS (213)   | 111            | 100             | 90.2 ^a         | 82 ^a   | 100 ^a  |
| Fillaux *et al.* [153] | MSG          | BAL (400)      | 66               | 100             | 90.5            | 47      | 100     |
| Chumpitazi *et al.* [151] | MSG          | BAL (66)       | 18               | 100             | 97.7            | 95.5    | 100     |

BAL: bronchoalveolar lavage; IS: induced sputum; NA: not available; NPV: negative predictive value; PPV: positive predictive value. ^a Calculated from data presented in a respective publication and in Chumpitazi *et al.* [151].

Moreover, as a period of colonization most likely precedes the development of acute PCP [158], this colonization should not be overlooked. Furthermore, “colonization” may have several important clinical implications because of stimulation of the inflammatory response within the lung [159–161]. As shown in chronic obstructive pulmonary disease, colonization may be involved in the development or progression of various lung diseases, suggesting the possible utility of treating these colonizations [162]. Finally, ongoing arguments suggest that a strict dichotomization of PCP and colonization is artificial because of a probable continuum of *Pneumocystis* infections from severe hypoxemia PCP to transient colonization in the immunocompetent.

6. Plasmatic Markers

As a non-specific marker for lung injury, the level of serum lactic dehydrogenase is elevated (>300 IU) in most patients with PCP [31]. Lactic dehydrogenase level can help indicate PCP [24] and correlates with severity of the disease [16]. However, this marker is not specific and is also increased in other pulmonary diseases [31].

There has been recent interest in using serum levels of β-D-glucan (BDG), a polysaccharide present in the *Pneumocystis* cyst wall but also in most fungi, as a noninvasive diagnostic test for PCP. Performance of commercial BDG assays have been examined in several studies with sensitivities ranging from 90% to 100% and specificities of 88%–96% in non-HIV-infected immunosuppressed patients with pneumonia [134,162–164]. However, the standardized cut-off values for clinical
infection have not been determined. Strategies to distinguish colonization from PCP are also proposed using BDG levels [165,166]. Although one study found a relationship with organism burden, BDG levels do not correlate with disease severity or the response to therapy, which makes this marker unsuitable for monitoring a response to treatment [134,164,167]. Moreover, BDG is present in the walls of most fungi [168,169] and its level is also increased in other fungal infections. Bacterial pneumonia [170] or β-lactam antibiotic administration (particularly piperacillin-tazobactam) [171] may also lead to false positive results. For this reason, BDG can be useful as an ancillary test in patients with a high suspicion of PCP.

7. Prophylaxis

7.1. General Considerations

While guidelines for PCP prophylaxis among HIV patients [172] are specific and universally accepted, there is a lack of consensus on the prophylaxis for other immunocompromised people. In SOT recipients, the highest risk period for the development of PCP is the first six months after transplantation [33,45–50], with a PCP incidence of about 10% (5%–15%) [16,28,29]. The use of a post-transplantation primary prophylaxis is now commonly accepted by the majority of the experts: nevertheless, the duration of treatment is still debated. In 2002, the European Renal Association recommended a PCP prophylaxis period of at least four months post-transplantation [173]. More recently, the Kidney Disease Improving Global Outcomes guidelines recommended 3–6 months [174], and the American Society of Transplantation Guidelines recommended 6–12 months [69,111] after transplantation [174] for all recipients, although longer durations could be considered [111]. Indeed, some data suggest that treatment duration can be prolonged to >1 year [25,31].

Although lifelong prophylaxis is not recommended for kidney-transplant recipients, it may be indicated for lung-, heart- and small-bowel-transplant recipients as the incidence of PCP is higher in this population [31,111]. Even if no consensus exists on the optimal duration of primary PCP prophylaxis, its generalized use in SOT recipients during the first months post-transplantation has drastically decreased the incidence of this infection during this period [16,175].

However, in many cases, PCP has occurred after the recommended post-transplantation prophylaxis period [27,176]. After this period, there are no clear recommendations for the re-initiation of anti-PCP prophylaxis. The risk threshold estimated by a peripheral CD4+ T-cell count of <200/μL and commonly used for HIV-positive patients [101,177] seems to not apply to HIV-negative immunocompromised patients and particularly not to SOT patients [20,122,178]. Instead, PCP risk factors identified in SOT recipients may help guide indications for chemoprophylaxis.

Patients with a history of a prior PCP infection, cytomegalovirus (CMV) infection, lymphopenia, prolonged neutropenia, or who require higher than usual levels of immune suppression, [31,32,111] may benefit from PCP prophylaxis, even if no clear consensus of duration is available. Strategies to target patients at high risk for PCP after the first year post-transplantation, in SOT recipients who benefit from initial TMP-SMX prophylaxis [27], using their age, date of transplantation, lymphocyte count, and presence of detectable CMV viremia, may also be considered. In addition, PCP prophylaxis
is recommended for kidney-transplant recipients for at least six weeks during and after treatment for an acute rejection [174].

7.2. Trimethoprim-Sulfamethoxazole (TMP-SMX)

TMP-SMX remains the drug of choice to prevent PCP in HIV-positive [179] or -negative patients [32,111] (Table 8). Several studies have shown the effectiveness of TMP-SMX prophylaxis in SOT recipients [30,41,49,175,180]. A Cochrane review showed that TMP-SMX prophylaxis was highly effective at preventing PCP in both HIV-negative children and adults [181]. Overall, TMP-SMX shows an 85% reduction in the incidence of PCP infections (RR 0.15, 95%CI: 0.04–0.62) and PCP-related mortality was reduced by 83% (RR 0.17, 95%CI: 0.03–0.94) [181]. For SOT recipients the RR was 0.09 (95%CI: 0.02–0.48) [181]. The common adult dose of TMP-SMX was 160/800 mg and it can be administered thrice weekly, as its efficacy is similar to once daily administration. The overall prevalence of severe adverse events with TMP-SMX is low. In the Cochrane review, no severe adverse events were observed with TMP-SMX among the trials that compared TMP-SMX to a placebo or no treatment [181]. Overall, in all the studies included in this meta-analysis that focused on TMP-SMX treatment, severe adverse events that required permanent discontinuation, including leukopenia, thrombocytopenia, or severe dermatological reactions, occurred in 3.1% of adults and 0% of children [181]. The most serious adverse effect was leukopenia [108,181]. Prophylactic TMP-SMX should be considered when the risk of PCP is >6.2% overall in patients not receiving prophylaxis [181], which includes for the first six months for those who have undergone solid-organ transplantation [31]. During outbreaks of PCP among immunocompromised patients, the incidence of PCP may be high enough to justify prophylaxis.

Table 8. Mean prophylactic and therapeutic options for Pneumocystis pneumonia (PCP).
Adapted from Martin et al. [111] and Catherinot et al. [52].

| Drug               | Prophylactic Regimen | Curative Regimen | Comments                                                                 |
|--------------------|----------------------|------------------|--------------------------------------------------------------------------|
| Trimethoprim—      | TMP: 80–160 mg—      | TMP: 15–20 mg/kg—| Contraindication in cases of allergy to sulfa drugs.                     |
| Sulfamethoxazole   | SMX: 400–800 mg,     | SMX: 75–100 mg/kg,| Adverse effects: Cytopenia, skin reactions,                             |
|                    | daily p.o. or IV     | IV or p.o., divided into 3–4 doses daily | hepatitis, pancreatitis, gastrointestinal disturbance,                  |
|                    | TMP: 160 mg—SMX:     |                  | renal insufficiency, hyperkalemia, anaphylaxis.                          |
|                    | 800 mg, 3 times weekly|                  | Interaction with cyclosporine: increase of creatinine level with possible decrease of cyclosporine plasmatic concentrations.|
|                    | p.o. or IV           |                  |                                                                          |
| Dapsone            | 50–100 mg, daily p.o.| -                | Contraindication in cases of G6PD deficiency.                           |
|                    |                      |                  | Possible cross-reaction with sulfa allergy. Adverse effects: methemoglobinemia, anemia, skin rash, gastrointestinal disturbance, agranulocytosis |
| Atovaquone         | 750 mg, 2 times daily p.o. | 750 mg, 2–3 times daily p.o. | Variable oral absorption. Adverse effects: skin rash, fever, gastrointestinal disturbance, hepatitis |
Table 8. Cont.

| Drug                  | Prophylactic Regimen          | Curative Regimen   | Comments                                                                 |
|-----------------------|-------------------------------|-------------------|---------------------------------------------------------------------------|
| Pentamidine           | 300 mg, monthly administered through aerosolized nebulizer | 4 mg/kg, daily IV | Adverse effects: pancreatitis, hypo- or hyperglycemia, bone-marrow suppression, renal insufficiency, cardiac arrhythmias, electrolyte disorders, hypotension, hepatitis. Interaction with others nephrotoxic drugs, increasing renal toxicity, particularly cyclosporine or tacrolimus |
| Dapsone + trimethoprim |                                | Dapsone: 100 mg, daily p.o. Trimethoprim: 5 mg/kg, 3 times daily | Contraindication in cases of G6PD deficiency. Possible cross-reaction with sulfa allergy. Adverse effects: methemoglobinemia, skin rash, fever, gastrointestinal disturbance |
| Clindamycin + primaquine |                                | Clindamycin: 600 mg, 4 times daily IV or 350–400 mg, 4 times daily p.o. Primaquine: 15–30 mg daily p.o. | Contraindication in cases of G6PD deficiency. Adverse effects: skin rash, fever, neutropenia, gastrointestinal disturbance, methemoglobinemia. Interaction with cyclosporine: possible decrease of cyclosporine plasmatic concentrations. |

7.3. Other Chemoprophylactic Agents

7.3.1. Dapsone

Dapsone is considered a second-line agent to prevent PCP after TMP-SMX therapy [111,182] (Table 8). It can be used in combination with pyrimethamine or trimethoprim. Because of its long half-life in plasma, dapsone may be administered in dosages of 50–100 mg daily to 100 mg weekly. However, dapsone must be avoided in G6PD or methemoglobin-reductase deficiency. Adverse events include agranulocytosis, aplastic anemia, rash, nausea, and sulfa reactions [183]. Intolerance may be more common among solid-organ transplant recipients [184] and often in those who are intolerant of TMP-SMX. A switch from TMP-SMX to dapsone is generally not recommended for patients with desquamation, neutropenia, interstitial nephritis, or hepatitis.

7.3.2. Atovaquone

Atovaquone is an inhibitor of the mitochondrial electron transport. In HIV patients, atovaquone seems to be equivalent to dapsone in preventing PCP [185] (Table 8). In solid-organ transplant recipients it appears to be effective and well tolerated [32,186] and may be an alternative PCP prophylaxis despite its unknown optimal dosage and its extremely variable absorption. Nevertheless, failures of atovaquone have been reported in patients taking 1000 mg or less daily [31,32]. The most common side effects generally do not require treatment to be discontinued: i.e., rash, headache, nausea, and diarrhea [35,187].
7.3.3. Pentamidine

Inhaled pentamidine (300 mg, every 3–4 weeks), administrated as droplets from a nebulizer, should be considered as a third-line agent [111] (Table 8). Pentamidine is well-tolerated with minimal side effects other than bronchospasms or a cough. Toxicity has been observed in 3%–7.5% of SOT recipients [188,189]. Nevertheless, it seems to be less effective than TMP-SMX, dapsone, or atovaquone, as the use of inhaled pentamidine has been associated with a higher incidence of breakthrough infections. Disseminated Pneumocystis infection [190,191] or PCP predominating in the upper lung lobes, with cystic formation and pneumothorax development [192,193] has occurred in HIV-patients receiving aerosolized pentamidine.

7.3.4. Other Agents or Combinations

Other agents or combinations (sulfadoxine-pyrimethamine, TMP-dapsone, clindamycin-primaquine, intravenous pentamidine) have been used with variable results but data are often insufficient to recommend these agents in practice [31].

7.4. Prophylaxis and Nosocomial Infections

As PCP outbreaks have been largely documented among kidney-transplant recipients [60–63,66,106,107], some authors recommend isolation of immunocompromised patients with PCP or patients in whom pulmonary colonization with P. jirovecii is diagnosed [194]. The use of a facemask to prevent aerial transmission of Pneumocystis may also be recommended to protect susceptible patients [63].

8. Treatments

8.1. Anti-Pneumocystis Agents

8.1.1. Trimethoprim-Sulfamethoxazole (TMP-SMX)

TMP-SMX is the first-line agent for the treatment of mild to severe PCP in both HIV and non-HIV-infected patients [195] (Table 8). Its combination with other anti-Pneumocystis agents is not recommended in the first instance [121]. TMP-SMX acts by interfering with folate metabolism (dihydrofolate reductase and dihydropteroate synthase) in Pneumocystis. TMP-SMX is also the drug of choice for SOT patients [111] because of its high efficacy and its availability in oral and parenteral forms. The recommended daily dose is TMP 15–20 mg/kg plus SMX 75–100 mg/kg, preferably by IV administration for severe PCP.

Monitoring of SMX drug levels is controversial for patients receiving IV therapy and no practical information is available in the current guidelines [196]. As TMP-SMX has excellent oral bioavailability, with concentration in serum most of the time, comparable to intravenous (IV) administration, oral administration seems adequate for non-severe patients who are able to take per os medications. Adverse reactions usually begin during the second week of treatment, but they occur less commonly in HIV-negative patients than in HIV-positive patients [110]. Recommended duration of treatment is
21 days in HIV-positive patients because of their higher fungal load and slower clinical response, with a higher risk of relapse after treatment [197]. For HIV-negative patients, such as SOT recipients, the optimal duration has not been fully studied but is generally 14 days [121]. This duration of therapy can be extended to 21 days in severe infections or when clinical improvement is prolonged [111].

The effectiveness of anti-Pneumocystis treatment (when corticosteroids are not associated) cannot be evaluated in the first days after beginning therapy as patients usually worsen during this period and only start to improve after 4–8 days [110]. If clinical improvement is not observed after 4–8 days, changes to the treatment should be made with an alternative IV drug. If the first-line agent was oral TMP-SMX, a switch can be made to an IV regimen [121]. Mutations in dihydropteroate synthetase (DHPS) have been described but no clear association between these mutations and failure of TMP-SMX treatment or altered outcomes have been demonstrated in AIDS patients [198,199].

8.1.2. Other Agents

Intravenous pentamidine is about as effective as TMP-SMX in AIDS-patients [200–202] and remains probably the best second-line agent after TMP-SMX for SOT recipients [111] (Table 8). Nevertheless, its use can be complicated by numerous toxicities in 71% of patients, leading to drug withdrawal in 18% [203]. Due to the potential for islet-cell necrosis, pentamidine must be avoided in cases of pancreas or islet transplantation [111]. Atovaquone, clindamycin-primaquine, or dapsone-TMP have only been evaluated in mild to moderate PCP in AIDS patients (Table 8). The clindamycin-primaquine combination seems to be the most effective regimen, particularly in cases where TMP-SMX has failed, as is associated with better outcomes as a second-line treatment compared to pentamidine in AIDS patients [204].

Few clinical data support the use of pyrimethamine–sulfadiazine, macrolide-SMX, or caspofungin-TMP-SMX, and the data are insufficient to recommend these agents in practice [205,206].

8.2. Adjuvant Corticosteroids

Adjunctive glucocorticoids are recommended for HIV-positive patients with moderate to severe PCP [197], defined as PaO$_2$ <70 mmHg while breathing ambient room air. The benefit to survival from corticosteroids begins during the first 72 h of treatment [52]. In HIV-negative patients with moderate-to-severe PCP, the use of adjunctive glucocorticoids remains questionable and is highly controversial [207,208]. No prospective trial has been conducted on HIV-negative patients. Recommendations are based on small-scale retrospective analyses, including very heterogeneous populations of patients, varying dosages of corticosteroids, and the conclusions are contradictory.

In four retrospective studies, there was no significant improvement in outcome with adjunctive steroid therapy [113,123,209,210], although Bolée et al.’s study [113] found a trend for longer survival in patients who received adjunctive steroids ($p = 0.07$). In Pareja et al.’s study, there was no difference in the mortality rates of patients treated with adjunctive high-dose steroids but they did spend less time on mechanical ventilation compared to patients not managed with steroids [18].

KDIGO and the American Society of Transplantation guidelines recommend treatment with adjunctive corticosteroids for SOT recipients with moderate to severe PCP (as defined by PaO$_2$ <70 mmHg in room air) [111,174]. Corticosteroids should be administered with antimicrobial
therapies, ideally within 72 h of initiating the antimicrobial therapy to obtain the maximum benefits [111]. The optimal dose of corticosteroids has not been well-established. American Society of Transplantation guidelines suggest that 40–60 mg of prednisone is administered per os twice daily and tapered after 5–7 days over a period of 1–2 weeks [111]. Nevertheless, in a recent retrospective study that included 139 HIV-negative patients with PCP, Lemiale et al. suggested that adjunctive high doses of corticosteroids (>1 mg/kg/day) increased the death rate [211]. Even though this study suffers from several limitations, such as having a retrospective design, a 23-year period of inclusion, a lack of information on the factors that governed the use or timing of corticosteroid initiation, these data challenge the recommendations on the use of corticosteroids for SOT recipients with PCP.

8.3. Reduction in Immunosuppressive Medications

The National Kidney Foundation recommends reducing immunosuppressive medications for kidney-transplant recipients who develop PCP [174]. Thus, this recommendation may logically be enlarged to all SOT recipients with PCP.

9. Conclusions

PCP remains an important cause of morbidity and mortality in SOT patients, even though the early post-transplantation period now carries a much lesser risk of infection because of the use of primary TMP-SMX as a prophylaxis. However, the occurrence of PCP after completion of a course of prophylaxis has now become problematic, particularly during the second year post-transplantation. As systematic PCP prophylaxis after the first year does not seem to be appropriate because of the low overall proportion of SOT patients who develop PCP, an individualized approach to target patients at risk seems to be a more relevant strategy. Because of the lack of biological parameter associated with a high risk for PCP, as occurs for AIDS patients, criteria based on risk factors identified for these patients, such as CMV infection, graft rejection, or lymphopenia, could be helpful in this context.

Even though a recent study shows that mortality seems to be lower in SOT recipients than in other types of immunocompromised patients, and comparable to that of AIDS patients, the prognosis remains closely related to the precocity of diagnosis and treatment. In SOT recipients, microbiological diagnosis must not be based on traditional microscopic methods. Molecular methods are highly effective in the diagnosis of PCP and have a highly negative predictive value close to 100%, which allows exclusion of PCP in SOT recipients with pneumonia. PCR methods or new approaches, such as detection of the β-D-glucan antigen, also facilitate a diagnosis of PCP in patients who cannot benefit from invasive sampling.

TMP-SMX is consensually considered as the first-line anti-\textit{Pneumocystis} agent, but the use of adjunctive glucocorticoids remains highly controversial and recommendations are based on small-scale retrospective studies as no prospective trial has been conducted on SOT recipients. In contrast to AIDS-positive patients, the most recent data suggest that a high dose of adjunctive glucocorticoids may be deleterious in HIV-negative patients.
Acknowledgments

The authors gratefully acknowledge Susanna Lyle for revision of the English text.

Conflicts of Interest

The authors of this manuscript have no conflicts of interest.

References

1. Roblot, F.; Godet, C.; le Moal, G.; Garo, B.; Faouzi Souala, M.; Dary, M.; de Gentile, L.; Gandji, J.A.; Guimard, Y.; Lacroix, C.; et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur. J. Clin. Microbiol. Infect. Dis. 2002, 21, 523–531.
2. Sepkowitz, K.A. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin. Infect. Dis. 2002, 34, 1098–1107.
3. Chabe, M.; Durand-Joly, I.; Dei-Cas, E. Transmission of Pneumocystis infection in humans. Med. Sci 2012, 28, 599–604.
4. Hughes, W.T. Natural mode of acquisition for de novo infection with Pneumocystis carinii. J. Infect. Dis. 1982, 145, 842–848.
5. Cushion, M.T.; Linke, M.J.; Ashbaugh, A.; Sesterhenn, T.; Collins, M.S.; Lynch, K.; Brubaker, R.; Walzer, P.D. Echinocandin treatment of Pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS ONE 2010, 5, e8524.
6. Martinez, A.; Halliez, M.C.; Aliouat el, M.; Chabe, M.; Standaert-Vitse, A.; Frealle, E.; Gantois, N.; Pottier, M.; Pinon, A.; Dei-Cas, E.; et al. Growth and airborne transmission of cell-sorted life cycle stages of Pneumocystis carinii. PLoS ONE 2013, 8, e79958.
7. Miller, R.F.; Ambrose, H.E.; Wakefield, A.E. Pneumocystis carinii f. sp. hominis DNA in immunocompetent health care workers in contact with patients with P. carinii pneumonia. J. Clin. Microbiol. 2001, 39, 3877–3882.
8. Manoloff, E.S.; Francioli, P.; Taffe, P.; Van Melle, G.; Bille, J.; Hauser, P.M. Risk for Pneumocystis carinii transmission among patients with pneumonia: A molecular epidemiology study. Emerg. Infect. Dis. 2003, 9, 132–134.
9. Nevez, G.; Raccurt, C.; Jounieaux, V.; Dei-Cas, E.; Mazars, E. Pneumocystosis versus pulmonary Pneumocystis carinii colonization in HIV-negative and HIV-positive patients. AIDS 1999, 13, 535–536.
10. Keely, S.P.; Stringer, J.R.; Baughman, R.P.; Linke, M.J.; Walzer, P.D.; Smulian, A.G. Genetic variation among Pneumocystis carinii hominis isolates in recurrent pneumocystosis. J. Infect. Dis. 1995, 172, 595–598.
11. Mansharamani, N.G.; Garland, R.; Delaney, D.; Koziel, H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: Comparison of HIV-associated cases to other immunocompromised states. Chest 2000, 118, 704–711.
12. Nuesch, R.; Bellini, C.; Zimmerli, W. *Pneumocystis carinii* pneumonia in human immunodeficiency virus (HIV)-positive and HIV-negative immunocompromised patients. *Clin. Infect. Dis.* **1999**, **29**, 1519–1523.

13. Monnet, X.; Vidal-Petiot, E.; Osman, D.; Hamzaoui, O.; Durrbach, A.; Gouyard, C.; Miceli, C.; Bouree, P.; Richard, C. Critical care management and outcome of severe *Pneumocystis* pneumonia in patients with and without HIV infection. *Crit. Care* **2008**, **12**, R28.

14. Mikaelsson, L.; Jacobsson, G.; Andersson, R. *Pneumocystis* pneumonia—a retrospective study 1991–2001 in Gothenburg; Sweden. *J. Infect.* **2006**, **53**, 260–265.

15. Teichtahl, A.J.; Morrisroe, K.; Ciciriello, S.; Jennens, I.; Tadros, S.; Wicks, I. *Pneumocystis jiroveci* pneumonia in connective tissue diseases. Comparison with other immunocompromised patients. *Semin. Arthritis Rheum.* **2015**, **45**, 86–90.

16. Gordon, S.M.; LaRosa, S.P.; Kalmadi, S.; Arroliga, A.C.; Avery, R.K.; Truesdell-LaRosa, L.; Longworth, D.L. Should prophylaxis for *Pneumocystis carinii* pneumonia in solid organ transplant recipients ever be discontinued? *Clin. Infect. Dis.* **1999**, **28**, 240–246.

17. Bourbigot, B.; Bensoussan, T.; Garo, B.; Islam, M.S.; Hardy, E.; Moal, M.C.; Garre, M. CD4 T-lymphocyte counts as predictors of pneumonia after kidney transplantation. *Transplant. Proc.* **1993**, **25**, 1491–1492.

18. Pareja, J.G.; Garland, R.; Koziel, H. Use of adjunctive corticosteroids in severe adult non-HIV *Pneumocystis carinii* pneumonia. *Chest* **1998**, **113**, 1215–1224.

19. Adler, D.; Chenivesse, C.; Similowski, T.; Soccal, P.M. *Pneumocystis* pneumonia in patients with immunosuppression other than HIV infection (in French). *Rev. Med. Suisse* **2008**, **4**, 2525–2526; 2528–2530.

20. Iriart, X.; Witkowski, B.; Cassaing, S.; Abbes, S.; Menard, S.; Filliaux, J.; Valentin, A.; Linas, M.D.; Tkaczuk, J.; Huget, F.; et al. Alveolar and blood T lymphocyte profiles in *Pneumocystis jirovecii*-positive patients: Effects of HIV status. *J. Infect. Dis.* **2011**, **204**, 544–553.

21. Magne, D.; Angoulvant, A.; Botterel, F.; Bouges-Michel, C.; Bougnoux, M.E.; Bouree, P.; Chochillon, C.; Cornet, M.; Dannaoui, E.; Fekkar, A.; et al. Pneumocystosis: A network survey in the Paris area 2003–2008. *Eur. J. Clin. Microbiol Infect. Dis.* **2011**, **30**, 673–675.

22. Roux, A.; Canet, E.; Valade, S.; Gangneux-Robert, F.; Hamane, S.; Lafabrie, A.; Maubon, D.; Debourgogne, A.; le Gal, S.; Dalle, F.; et al. *Pneumocystis jirovecii* pneumonia in patients with or without AIDS, France. *Emerg. Infect. Dis.* **2014**, **20**, 1490–1497.

23. Anand, S.; Samaniego, M.; Kaul, D.R. *Pneumocystis jirovecii* pneumonia is rare in renal transplant recipients receiving only one month of prophylaxis. *Transpl. Infect. Dis.* **2011**, **13**, 570–574.

24. Borstnar, S.; Lindic, J.; Tomazic, J.; Kandus, A.; Pikelj, A.; Prah, J.; Skvarc, M.; Godnov, U.; Kovac, D. *Pneumocystis jirovecii* pneumonia in renal transplant recipients: A national center experience. *Transplant. Proc.* **2013**, **45**, 1614–1617.

25. Wang, E.H.; Partovi, N.; Levy, R.D.; Shapiro, R.J.; Yoshida, E.M.; Greanya, E.D. *Pneumocystis* pneumonia in solid organ transplant recipients: Not yet an infection of the past. *Transpl. Infect. Dis.* **2012**, **14**, 519–525.
26. De Boer, M.G.; Kroon, F.P.; le Cessie, S.; de Fijtrter, J.W.; van Dissel, J.T. Risk factors for *Pneumocystis jirovecii* pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis. *Transpl. Infect. Dis.* 2011, 13, 559–569.

27. Iriart, X.; Challan Belval, T.; Fillaux, J.; Esposito, L.; Lavergne, R.A.; Cardeau-Desangles, I.; Roques, O.; Del Bello, A.; Cointault, O.; Lavayssiere, L.; *et al.* Risk factors of *Pneumocystis* pneumonia in solid organ recipients in the era of the common use of posttransplantation prophylaxis. *Am. J. Transplant.* 2015, 15, 190–199.

28. Fishman, J.A. Prevention of infection due to *Pneumocystis carinii*. *Antimicrob. Agents Chemother.* 1998, 42, 995–1004.

29. Struijk, G.H.; Gijsen, A.F.; Yong, S.L.; Zwinderman, A.H.; Geerlings, S.E.; Lettinga, K.D.; van Donselaar-van der Pant, K.A.; ten Berge, I.J.; Bemelman, F.J. Risk of *Pneumocystis jiroveci* pneumonia in patients long after renal transplantation. *Nephrol. Dial. Transplant.* 2011, 26, 3391–3398.

30. Munoz, P.; Munoz, R.M.; Palomo, J.; Rodriguez-Creixems, M.; Munoz, R.; Bouza, E. *Pneumocystis carinii* infection in heart transplant recipients: Efficacy of a weekend prophylaxis schedule. *Medicine* 1997, 76, 415–422.

31. Rodriguez, M.; Fishman, J.A. Prevention of infection due to *Pneumocystis spp.* in human immunodeficiency virus-negative immunocompromised patients. *Clin. Microbiol. Rev.* 2004, 17, 770–782.

32. Fishman, J.A. Prevention of infection caused by *Pneumocystis carinii* in transplant recipients. *Clin. Infect. Dis.* 2001, 33, 1397–1405.

33. Lufft, V.; Kliem, V.; Behrend, M.; Pichlmayr, R.; Koch, K.M.; Brunkhorst, R. Incidence of *Pneumocystis carinii* pneumonia after renal transplantation: Impact of immunosuppression. *Transplantation* 1996, 62, 421–423.

34. Sepkowitz, K.A.; Brown, A.E.; Armstrong, D. *Pneumocystis carinii* pneumonia without acquired immunodeficiency syndrome: More patients; same risk. *Arch. Intern. Med.* 1995, 155, 1125–1128.

35. Colombo, J.L.; Sammut, P.H.; Langnas, A.N.; Shaw, B.W., Jr. The spectrum of *Pneumocystis carinii* infection after liver transplantation in children. *Transplantation* 1992, 54, 621–624.

36. Hayes, M.J.; Torzillo, P.J.; Sheil, A.G.; McCaughan, G.W. *Pneumocystis carinii* pneumonia after liver transplantation in adults. *Clin. Transplant.* 1994, 8, 499–503.

37. Paya, C.V.; Hermans, P.E.; Washington, J.A., 2nd; Smith, T.F.; Anhalt, J.P.; Wiesner, R.H.; Krom, R.A. Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations. *Mayo Clin. Proc.* 1989, 64, 555–564.

38. Choi, Y.I.; Hwang, S.; Park, G.C.; Namgoong, J.M.; Jung, D.H.; Song, G.W.; Ha, T.Y.; Moon, D.B.; Kim, K.H.; Ahn, C.S.; *et al.* Clinical outcomes of *Pneumocystis carinii* pneumonia in adult liver transplant recipients. *Transplant. Proc.* 2013, 45, 3057–3060.

39. Gryzan, S.; Paradis, I.L.; Zeevi, A.; Duquesnoy, R.J.; Dummer, J.S.; Griffith, B.P.; Hardesty, R.L.; Trento, A.; Nalesnik, M.A.; Dauber, J.H. Unexpectedly high incidence of *Pneumocystis carinii* infection after lung-heart transplantation: Implications for lung defense and allograft survival. *Am. Rev. Respir Dis.* 1988, 137, 1268–1274.

40. Janner, D.; Bork, J.; Baum, M.; Chinnock, R. *Pneumocystis carinii* pneumonia in infants after heart transplantation. *J. Heart Lung Transplant.* 1996, 15, 758–763.
41. Olsen, S.L.; Renlund, D.G.; O’Connell, J.B.; Taylor, D.O.; Lasseter, J.E.; Eastburn, T.E.; Hammond, E.H.; Bristow, M.R. Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole. Transplantation 1993, 56, 359–362.
42. Dummer, J.S.; Montero, C.G.; Griffith, B.P.; Hardesty, R.L.; Paradis, I.L.; Ho, M. Infections in heart-lung transplant recipients. Transplantation 1986, 41, 725–729.
43. Radisic, M.; Lattes, R.; Chapman, J.F.; del Carmen Rial, M.; Guardia, O.; Seu, F.; Gutierrez, P.; Goldberg, J.; Casadei, D.H. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: A case-control study. Transpl. Infect. Dis. 2003, 5, 84–93.
44. Fillatre, P.; Decaux, O.; Jouneau, S.; Revest, M.; Gacouin, A.; Robert-Gangneux, F.; Fresnel, A.; Guiguen, C.; le Tulzo, Y.; Jego, P.; et al. Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. Am. J. Med. 2014, 127, 1242.e11–1242.e17.
45. Hardy, A.M.; Wajszczuk, C.P.; Suffredini, A.F.; Hakala, T.R.; Ho, M. Pneumocystis carinii pneumonia in renal-transplant recipients treated with cyclosporine and steroids. J. Infect. Dis. 1984, 127, 920–925.
46. Dummer, J.S. Pneumocystis carinii infections in transplant recipients. Semin. Respir. Infect. 1990, 5, 50–57.
47. Elinder, C.G.; Andersson, J.; Bolinder, G.; Tyden, G. Effectiveness of low-dose cotrimoxazole prophylaxis against Pneumocystis carinii pneumonia after renal and/or pancreas transplantation. Transpl. Int. 1992, 5, 81–84.
48. Hennequin, C.; Page, B.; Roux, P.; Legendre, C.; Kreis, H. Outbreak of Pneumocystis carinii pneumonia in a renal transplant unit. Eur. J. Clin. Microbiol. Infect. Dis. 1995, 14, 122–126.
49. Arend, S.M.; Westendorp, R.G.; Kroon, F.P.; van’t Wout, J.W.; Vandenbroucke, J.P.; van Es, L.A.; van der Woude, F.J. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin. Infect. Dis. 1996, 22, 920–925.
50. Green, H.; Paul, M.; Vidal, L.; Leibovici, L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst. Rev. 2007, doi:10.1002/14651858.CD005590.pub2.
52. Catherinot, E.; Lanternier, F.; Bougnoux, M.E.; Lecuit, M.; Couderc, L.J.; Lortholary, O. Pneumocystis jirovecii Pneumonia. Infect. Dis. Clin. North. Am. 2010, 24, 107–138.
53. Cushion, M.T. Are members of the fungal genus Pneumocystis (a) commensals; (b) opportunists, (c) pathogens; or (d) all of the above? PLoS Pathog. 2010, 6, e1001009.
54. Lubis, N.; Baylis, D.; Short, A.; Stebbing, J.; Teague, A.; Portsmouth, S.; Bower, M.; Nelson, M.; Gazzard, B. Prospective cohort study showing changes in the monthly incidence of Pneumocystis carinii pneumonia. Postgrad. Med. J. 2003, 79, 164–166.
55. Miller, R.F.; Grant, A.D.; Foley, N.M. Seasonal variation in presentation of Pneumocystis carinii pneumonia. Lancet 1992, 339, 747–748.
56. Varela, J.M.; Regordan, C.; Medrano, F.J.; Respaldiza, N.; de La Horra, C.; Montes-Cano, M.A.; Calderon, E.J. Climatic factors and Pneumocystis jiroveci infection in southern Spain. Clin. Microbiol. Infect. 2004, 10, 770–772.
57. Sing, A.; Schmoldt, S.; Laubender, R.P.; Heesemann, J.; Sing, D.; Wildner, M. Seasonal variation of Pneumocystis jirovecii infection: Analysis of underlying climatic factors. Clin. Microbiol. Infect. 2009, 15, 957–960.

58. Miller, R.F.; Evans, H.E.; Copas, A.J.; Huggett, J.F.; Edwards, S.G.; Walzer, P.D. Seasonal variation in mortality of Pneumocystis jirovecii pneumonia in HIV-infected patients. Int. J. STD AIDS 2010, 21, 497–503.

59. De Boer, M.G.; de Fijter, J.W.; Kroon, F.P. Outbreaks and clustering of Pneumocystis pneumonia in kidney transplant recipients: A systematic review. Med. Mycol. 2011, 49, 673–680.

60. Arichi, N.; Kishikawa, H.; Mitsui, Y.; Kato, T.; Nishimura, K.; Tachikawa, R.; Tomii, K.; Shiina, H.; Igawa, M.; Ichikawa, Y. Cluster outbreak of Pneumocystis pneumonia among kidney transplant patients within a single center. Transplant. Proc. 2009, 41, 170–172.

61. De Boer, M.G.; Bruijnesteijn van Coppenraet, L.E.; Gaasbeek, A.; Berger, S.P.; Gelinck, L.B.; van Houwelingen, H.C.; van den Broek, P.; Kuijper, E.J.; Kroon, F.P.; Vandenbroucke, J.P. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: Interhuman transmission or a common environmental source? Clin. Infect. Dis. 2007, 44, 1143–1149.

62. Hocker, B.; Wendt, C.; Nahimana, A.; Tonshoff, B.; Hauser, P.M. Molecular evidence of Pneumocystis transmission in pediatric transplant unit. Emerg. Infect. Dis. 2005, 11, 330–332.

63. Schmoldt, S.; Schuhegger, R.; Wendler, T.; Huber, I.; Sollner, H.; Hogardt, M.; Arbogast, H.; Heesemann, J.; Bader, L.; Sing, A. Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J. Clin. Microbiol. 2008, 46, 966–971.

64. Rabodonirina, M.; Vanhems, P.; Couray-Targe, S.; Gillibert, R.P.; Ganne, C.; Nizard, N.; Colin, C.; Fabry, J.; Touraine, J.L.; van Melle, G.; et al. Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV-infected patients. Emerg. Infect. Dis. 2004, 10, 1766–1773.

65. Phipps, L.M.; Chen, S.C.; Kable, K.; Halliday, C.L.; Firacative, C.; Meyer, W.; Wong, G.; Nankivell, B.J. Nosocomial Pneumocystis jirovecii pneumonia: Lessons from a cluster in kidney transplant recipients. Transplantation 2011, 92, 1327–1334.

66. Le Gal, S.; Damiani, C.; Rouille, A.; Grall, A.; Treguer, L.; Virmaux, M.; Moalic, E.; Quinio, D.; Moal, M.C.; Berthou, C.; et al. A cluster of Pneumocystis infections among renal transplant recipients: Molecular evidence of colonized patients as potential infectious sources of Pneumocystis jirovecii. Clin. Infect. Dis. 2012, 54, e62–e71.

67. Bartlett, M.S.; Vermund, S.H.; Jacobs, R.; Durant, P.J.; Shaw, M.M.; Smith, J.W.; Tang, X.; Lu, J.J.; Li, B.; Jin, S.; et al. Detection of Pneumocystis carinii DNA in air samples: Likely environmental risk to susceptible persons. J. Clin. Microbiol. 1997, 35, 2511–2513.

68. Olsson, M.; Lidman, C.; Latouche, S.; Bjorkman, A.; Roux, P.; Linder, E.; Wahlgren, M. Identification of Pneumocystis carinii f. sp. hominis gene sequences in filtered air in hospital environments. J. Clin. Microbiol. 1998, 36, 1737–1740.

69. Martin, S.I.; Fishman, J.A. Pneumocystis pneumonia in solid organ transplant recipients. Am. J. Transplant. 2009, 9, S227–S233.
70. Dominguez, J.; Mahalati, K.; Kiberd, B.; McAlister, V.C.; MacDonald, A.S. Conversion to rapamycin immunosuppression in renal transplant recipients: Report of an initial experience. *Transplantation* **2000**, *70*, 1244–1247.

71. Neff, R.T.; Jindal, R.M.; Yoo, D.Y.; Hurst, F.P.; Agodoa, L.Y.; Abbott, K.C. Analysis of USRDS: Incidence and risk factors for *Pneumocystis jiroveci* pneumonia. *Transplantation* **2009**, *88*, 135–141.

72. Franson, T.R.; Kauffman, H.M., Jr.; Adams, M.B.; Lemann, J., Jr.; Cabrera, E.; Hanacik, L. Cyclosporine therapy and refractory *Pneumocystis carinii* pneumonia: A potential association. *Arch. Surg.* **1987**, *122*, 1034–1035.

73. Strom, T.B. Immunosuppressive agents in renal transplantation. *Kidney Int.* **1984**, *26*, 353–365.

74. Kreis, H. Antilymphocyte globulins in kidney transplantation. *Kidney Int. Suppl.* **1992**, *38*, S188–S192.

75. Dantal, J.; Soulillou, J.P. Use of monoclonal antibodies in human transplantation. *Curr. Opin. Immunol.* **1991**, *3*, 740–747.

76. Fishman, J.A. Infection in renal transplant recipients. *Semin. Nephrol.* **2007**, *27*, 445–461.

77. Reid, A.B.; Chen, S.C.; Worth, L.J. *Pneumocystis jiroveci* pneumonia in non-HIV-infected patients: New risks and diagnostic tools. *Curr. Opin. Infect. Dis.* **2011**, *24*, 534–544.

78. Martin, S.I.; Marty, F.M.; Fiumara, K.; Treon, S.P.; Gribben, J.G.; Baden, L.R. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. *Clin. Infect. Dis.* **2006**, *43*, 16–24.

79. Eitner, F.; Hauser, I.A.; Rettkowski, O.; Rath, T.; Lopau, K.; Pliquett, R.U.; Fiedler, R.; Guba, M.; Hilgers, R.D.; Floge, J.; Fischereder, M. Risk factors for *Pneumocystis jiroveci* pneumonia (PcP) in renal transplant recipients. *Nephrol Dial. Transplant.* **2011**, *26*, 2013–2017.

80. Haynes, R.C. *Adrenocorticotropic Hormone: Adrenocortical Steroids and Their Synthetic Analogs, Inhibitors of the Synthesis and Actions of Adrenocortical Hormones*; Pergamon Press: New York, NY, USA, 1990.

81. Schaffner, A.; Schaffner, T. Glucocorticoid-induced impairment of macrophage antimicrobial activity: Mechanisms and dependence on the state of activation. *Rev. Infect. Dis.* **1987**, *9*, S620–S629.

82. Russo-Marie, F. Macrophages and the glucocorticoids. *J. Neuroimmunol.* **1992**, *40*, 281–286.

83. Ten Berge, R.J.; Sauerwein, H.P.; Yong, S.L.; Schellekens, P.T. Administration of prednisolone *in vivo* affects the ratio of OKT4/OKT8 and the LDH-isoenzyme pattern of human T lymphocytes. *Clin. Immunol. Immunopathol.* **1984**, *30*, 91–103.

84. Sepkowitz, K.A.; Brown, A.E.; Telzak, E.E.; Gottlieb, S.; Armstrong, D. *Pneumocystis carinii* pneumonia among patients without AIDS at a cancer hospital. *JAMA* **1992**, *267*, 832–837.

85. Yale, S.H.; Limper, A.H. *Pneumocystis carinii* pneumonia in patients without acquired immunodeficiency syndrome: Associated illness and prior corticosteroid therapy. *Mayo Clin. Proc.* **1996**, *71*, 5–13.

86. De Castro, N.; Xu, F.; Porcher, R.; Pavie, J.; Molina, J.M.; Peraldi, M.N. *Pneumocystis jirovecii* pneumonia in renal transplant recipients occurring after discontinuation of prophylaxis: A case-control study. *Clin. Microbiol. Infect.* **2010**, *16*, 1375–1377.
87. Ransom, J.T. Mechanism of action of mycophenolate mofetil. *Ther. Drug Monit.* **1995**, *17*, 681–684.
88. Oz, H.S.; Hughes, W.T. Novel anti-*Pneumocystis carinii* effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. *J. Infect. Dis.* **1997**, *175*, 901–904.
89. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. *Lancet* **1995**, *345*, 1321–1325.
90. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. *Transplantation* **1996**, *61*, 1029–1037.
91. Sollinger, H.W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. *Transplantation* **1995**, *60*, 225–232.
92. Ritter, M.L.; Pirofski, L. Mycophenolate mofetil: Effects on cellular immune subsets, infectious complications, and antimicrobial activity. *Transpl. Infect. Dis.* **2009**, *11*, 290–297.
93. Gianella, S.; Haeberli, L.; Joos, B.; Ledergerber, B.; Wuthrich, R.P.; Weber, R.; Kuster, H.; Hauser, P.M.; Fehr, T.; Mueller, N.J. Molecular evidence of interhuman transmission in an outbreak of *Pneumocystis jirovecii* pneumonia among renal transplant recipients. *Transpl. Infect. Dis.* **2010**, *12*, 1–10.
94. Rostved, A.A.; Sassi, M.; Kurtzhals, J.A.; Sorensen, S.S.; Rasmussen, A.; Ross, C.; Gogineni, E.; Huber, C.; Kutty, G.; Kovacs, J.A.; et al. Outbreak of *Pneumocystis* Pneumonia in Renal and Liver Transplant Patients Caused by Genotypically Distinct Strains of *Pneumocystis jirovecii*. *Transplantation* **2013**, *96*, 834–842.
95. Azevedo, L.S.; Castro, M.C.; Paula, F.J.; Ianhez, L.E.; David-Neto, E. Mycophenolate mofetil may protect against *Pneumocystis carinii* pneumonia in renal transplanted patients. *Rev. Inst. Med. Trop. Sao Paulo* **2005**, *47*, 143–145.
96. Kahan, B.D.; Julian, B.A.; Pescovit, M.D.; Vanrenterghem, Y.; Neylan, J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: A phase II trial. Rapamune Study Group. *Transplantation* **1999**, *68*, 1526–1532.
97. Andres, A.M.; Lopez Santamaria, M.; Ramos, E.; Hernandez, F.; Prieto, G.; Encinas, J.; Leal, N.; Molina, M.; Sarria, J.; Tovar, J. The use of sirolimus as a rescue therapy in pediatric intestinal transplant recipients. *Pediatr. Transplant.* **2010**, *14*, 931–935.
98. Pliquett, R.U.; Asbe-Vollkopf, A.; Hauser, P.M.; Presti, L.L.; Hunfeld, K.P.; Berger, A.; Scheuermann, E.H.; Jung, O.; Geiger, H.; Hauser, I.A. A *Pneumocystis jirovecii* pneumonia outbreak in a single kidney-transplant center: Role of cytomegalovirus co-infection. *Eur. J. Clin. Microbiol. Infect. Dis.* **2012**, *31*, 2429–2437.
99. Linnemann, C.C., Jr.; Kauffman, C.A.; First, M.R.; Schiff, G.M.; Phair, J.P. Cellular immune response to cytomegalovirus infection after renal transplantation. * Infect. Immun.* **1978**, *22*, 176–180.
100. Beck, J.M.; Harmsen, A.G. Lymphocytes in host defense against Pneumocystis carinii. *Semin. Respir. Infect.* **1998**, *13*, 330–338.

101. Masur, H.; Ognibene, F.P.; Yarchoan, R.; Shelhamer, J.H.; Baird, B.F.; Travis, W.; Suffredini, A.F.; Deyton, L.; Kovacs, J.A.; Falloon, J.; *et al.* CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. *Ann. Intern. Med.* **1989**, *111*, 223–231.

102. Nevez, G.; Raccurt, C.; Vincent, P.; Jounieaux, V.; Dei-Cas, E. Pulmonary colonization with *Pneumocystis carinii* in human immunodeficiency virus-negative patients: Assessing risk with blood CD4+ T cell counts. *Clin. Infect. Dis.* **1999**, *29*, 1331–1332.

103. Castagnola, E.; Dini, G.; Lanino, E.; Tasso, L.; Dallorso, S.; Garaventa, A.; Rossi, G.A.; Giacchino, R. Low CD4 lymphocyte count in a patient with *P. carinii* pneumonia after autologous bone marrow transplantation. *Bone Marrow Transplant.* **1995**, *15*, 977–978.

104. Mansharamani, N.G.; Balachandran, D.; Vernovsky, I.; Garland, R.; Koziel, H. Peripheral blood CD4+ T-lymphocyte counts during *Pneumocystis carinii* pneumonia in immunocompromised patients without HIV infection. *Chest* **2000**, *118*, 712–720.

105. Kelly, M.N.; Shellito, J.E. Current understanding of *Pneumocystis* immunology. *Future Microbiol.* **2010**, *5*, 43–65.

106. Sassi, M.; Ripamonti, C.; Mueller, N.J.; Yazaki, H.; Kutty, G.; Ma, L.; Huber, C.; Gogineni, E.; Oka, S.; Goto, N.; *et al.* Outbreaks of *Pneumocystis* pneumonia in 2 renal transplant centers linked to a single strain of *Pneumocystis*: Implications for transmission and virulence. *Clin. Infect. Dis.* **2012**, *54*, 1437–1444.

107. Yazaki, H.; Goto, N.; Uchida, K.; Kobayashi, T.; Gatanaga, H.; Oka, S. Outbreak of *Pneumocystis jiroveci* pneumonia in renal transplant recipients: *P. jiroveci* is contagious to the susceptible host. *Transplantation* **2009**, *88*, 380–385.

108. Mitsides, N.; Greenan, K.; Green, D.; Middleton, R.; Lamerton, E.; Allen, J.; Redshaw, J.; Chadwick, P.R.; Subudhi, C.P.; Wood, G. Complications and outcomes of trimethoprim-sulphamethoxazole as chemoprophylaxis for *Pneumocystis* pneumonia in renal transplant recipients. *Nephrology* **2014**, *19*, 157–163.

109. Russian, D.A.; Levine, S.J. *Pneumocystis carinii* pneumonia in patients without HIV infection. *Am. J. Med. Sci.* **2001**, *321*, 56–65.

110. Kovacs, J.A.; Hiemenz, J.W.; Macher, A.M.; Stover, D.; Murray, H.W.; Shelhamer, J.; Lane, H.C.; Urmacher, C.; Honig, C.; Longo, D.L.; *et al.* *Pneumocystis carinii* pneumonia: A comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. *Ann. Intern. Med.* **1984**, *100*, 663–671.

111. Martin, S.I.; Fishman, J.A. *Pneumocystis* pneumonia in solid organ transplantation. *Am. J. Transplant.* **2013**, *13*, 272–279.

112. Ewig, S.; Bauer, T.; Schneider, C.; Pickenhain, A.; Pizzulli, L.; Loos, U.; Luderitz, B. Clinical characteristics and outcome of *Pneumocystis carinii* pneumonia in HIV-infected and otherwise immunosuppressed patients. *Eur. Respir. J.* **1995**, *8*, 1548–1553.

113. Bollee, G.; Sarfati, C.; Thiery, G.; Bergeron, A.; de Miranda, S.; Menotti, J.; de Castro, N.; Tazi, A.; Schlemmer, B.; Azoulay, E. Clinical picture of *Pneumocystis jiroveci* pneumonia in cancer patients. *Chest* **2007**, *132*, 1305–1310.
114. Walzer, P.D.; Perl, D.P.; Krogstad, D.J.; Rawson, P.G.; Schultz, M.G. *Pneumocystis carinii* pneumonia in the United States: Epidemiologic, diagnostic, and clinical features. *Ann. Intern. Med.* 1974, 80, 83–93.

115. McKinnell, J.A.; Cannella, A.P.; Kunz, D.F.; Hook, E.W.; 3rd; Moser, S.A.; Miller, L.G.; Baddley, J.W.; Pappas, P.G. *Pneumocystis* pneumonia in hospitalized patients: A detailed examination of symptoms, management, and outcomes in human immunodeficiency virus (HIV)-infected and HIV-uninfected persons. *Transpl. Infect. Dis.* 2012, 14, 510–518.

116. Santiago-Delpin, E.A.; Mora, E.; Gonzalez, Z.A.; Morales-Otero, L.A.; Bermudez, R. Factors in an outbreak of *Pneumocystis carinii* in a transplant unit. *Transplant. Proc.* 1988, 20, 462–465.

117. Talseth, T.; Holdaas, H.; Albrechtsen, D.; Berg, K.J.; Fauchald, P.; Naalsund, A.; Nordal, K.P.; Skar, A.G.; Sodal, G.; Flatmark, A. Increasing incidence of *Pneumocystis carinii* pneumonia in renal transplant patients. *Transplant. Proc.* 1988, 20, 400–401.

118. Sugimoto, H.; Uchida, H.; Akiyama, N.; Nagao, T.; Tomikawa, S.; Mita, K.; Beck, Y.; Inoue, S.; Watanabe, K.; Nakayama, Y.; et al. Improved survival of renal allograft recipients with *Pneumocystis carinii* pneumonia by early diagnosis and treatment. *Transplant. Proc.* 1992, 24, 1556–1558.

119. Zaoutis, T.E.; Webber, S.; Naftel, D.C.; Chrisant, M.A.; Kaufman, B.; Pearce, F.B.; Spicer, R.; Dipchand, A.I. Invasive fungal infections in pediatric heart transplant recipients: Incidence, risk factors, and outcomes. *Pediatr. Transplant.* 2011, 15, 465–469.

120. Ng, B.; Dipchand, A.; Naftel, D.; Ruseoni, P.; Boyle, G.; Zaoutis, T.; Edens, R.E. Outcomes of *Pneumocystis jiroveci* pneumonia infections in pediatric heart transplant recipients. *Pediatr. Transplant.* 2011, 15, 844–848.

121. Roux, A.; Gonzalez, F.; Roux, M.; Mehrad, M.; Menotti, J.; Zahar, J.R.; Tadros, V.X.; Azoulay, E.; Brillet, P.Y.; Vincent, F. Update on pulmonary *Pneumocystis jirovecii* infection in non-HIV patients. *Med. Mal. Infect.* 2014, 44, 185–198.

122. Toper, C.; Rivaud, E.; Daniel, C.; Cerf, C.; Parquin, F.; Catherinot, E.; Honderlick, P.; Escande, M.C.; Dreyfus, J.F.; Stern, M.; et al. *Pneumocystis jiroveci* pneumonia in non-HIV infected patients: A study of 41 cases. *Rev. Pneumol. Clin.* 2011, 67, 191–198.

123. Zahar, J.R.; Robin, M.; Azoulay, E.; Fioux, F.; Nitenberg, G.; Schlemmer, B. *Pneumocystis carinii* pneumonia in critically ill patients with malignancy: A descriptive study. *Clin. Infect. Dis.* 2002, 35, 929–934.

124. Limper, A.H.; Offord, K.P.; Smith, T.F.; Martin, W.J., 2nd. *Pneumocystis carinii* pneumonia: Differences in lung parasite number and inflammation in patients with and without AIDS. *Am. Rev. Respir. Dis.* 1989, 140, 1204–1209.

125. DeLorenzo, L.J.; Huang, C.T.; Maguire, G.P.; Stone, D.J. Roentgenographic patterns of *Pneumocystis carinii* pneumonia in 104 patients with AIDS. *Chest* 1987, 91, 323–327.

126. Boiselle, P.M.; Crans, C.A., Jr.; Kaplan, M.A. The changing face of *Pneumocystis carinii* pneumonia in AIDS patients. *Am. J. Roentgenol.* 1999, 172, 1301–1309.

127. Kanne, J.P.; Yandow, D.R.; Meyer, C.A. *Pneumocystis jiroveci* pneumonia: High-resolution CT findings in patients with and without HIV infection. *AJR Am. J. Roentgenol.* 2012, 198, W555–W561.
128. Fujii, T.; Nakamura, T.; Iwamoto, A. Pneumocystis pneumonia in patients with HIV infection: Clinical manifestations, laboratory findings, and radiological features. J. Infect. Chemother. 2007, 13, 1–7.

129. Vogel, M.N.; Brodoeffel, H.; Hierl, T.; Beck, R.; Bethge, W.A.; Claussen, C.D.; Horger, M.S. Differences and similarities of cytomegalovirus and Pneumocystis pneumonia in HIV-negative immunocompromised patients thin section CT morphology in the early phase of the disease. Br. J. Radiol. 2007, 80, 516–523.

130. Vogel, M.N.; Vatlach, M.; Weissgerber, P.; Goeppert, B.; Claussen, C.D.; Hetzel, J.; Horger, M. HRCT-features of Pneumocystis jiroveci pneumonia and their evolution before and after treatment in non-HIV immunocompromised patients. Eur. J. Radiol. 2012, 81, 1315–1320.

131. Thomas, C.F., Jr.; Limper, A.H. Pneumocystis pneumonia: Clinical presentation and diagnosis in patients with and without acquired immune deficiency syndrome. Semin. Respir. Infect. 1998, 13, 289–295.

132. Helweg-Larsen, J.; Jensen, J.S.; Lundgren, B. Non-invasive diagnosis of Pneumocystis carinii pneumonia by PCR on oral washes. Lancet 1997, 350, 1363.

133. Larsen, H.H.; Huang, L.; Kovacs, J.A.; Crothers, K.; Silcott, V.A.; Morris, A.; Turner, J.R.; Beard, C.B.; Masur, H.; Fischer, S.H. A prospective, blinded study of quantitative touch-down polymerase chain reaction using oral-wash samples for diagnosis of Pneumocystis pneumonia in HIV-infected patients. J. Infect. Dis. 2004, 189, 1679–1683.

134. De Boer, M.G.; Gelinck, L.B.; van Zelst, B.D.; van de Sande, W.W.; Willems, L.N.; van Dissel, J.T.; de Jonge, R.; Kroon, F.P. β-D-glucan and S-adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia in HIV-negative patients: A prospective study. J. Infect. 2011, 62, 93–100.

135. Lau, W.K.; Young, L.S.; Remington, J.S. Pneumocystis carinii pneumonia: Diagnosis by examination of pulmonary secretions. JAMA 1976, 236, 2399–2402.

136. Kovacs, J.A.; Ng, V.L.; Masur, H.; Leoung, G.; Hadley, W.K.; Evans, G.; Lane, H.C.; Ognibene, F.P.; Shellhamer, J.; Parrillo, J.E.; et al. Diagnosis of Pneumocystis carinii pneumonia: Improved detection in sputum with use of monoclonal antibodies. N. Engl. J. Med. 1988, 318, 589–593.

137. Fishman, J.A. Pneumocystis carinii and Parasitic Infections in the Immunocompromised Host; Kluwer Academic/Plenum Publishers: New York, NY, USA, 2002.

138. Stover DE; Zaman MB; Hajdu SI; Lange M; Gold J; Armstrong D. Bronchoalveolar lavage in the diagnosis of diffuse pulmonary infiltrates in the immunosuppressed host. Ann. Intern. Med. 1984, 101, 1–7.

139. Broadus, C.; Dake, M.D.; Stulbarg, M.S.; Blumenfeld, W.; Hadley, W.K.; Golden, J.A.; Hopewell, P.C. Bronchoalveolar lavage and transbronchial biopsy for the diagnosis of pulmonary infections in the acquired immunodeficiency syndrome. Ann. Intern. Med. 1985, 102, 747–752.

140. Rossiter, S.J.; Miller, C.; Churg, A.M.; Carrington, C.B.; Mark, J.B. Open lung biopsy in the immunosuppressed patient: Is it really beneficial? J. Thorac. Cardiovasc. Surg. 1979, 77, 338–345.

141. Thomas, C.F., Jr.; Limper, A.H. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat. Rev. Microbiol. 2007, 5, 298–308.
142. Thomas, C.F., Jr.; Limper, A.H. *Pneumocystis* pneumonia. *N. Engl. J. Med.* 2004, 350, 2487–2498.
143. Weig, M.; Klinker, H.; Bogner, B.H.; Meier, A.; Gross, U. Usefulness of PCR for diagnosis of *Pneumocystis carinii* pneumonia in different patient groups. *J. Clin. Microbiol.* 1997, 35, 1445–1449.
144. Ribes, J.A.; Limper, A.H.; Espy, M.J.; Smith, T.F. PCR detection of *Pneumocystis carinii* in bronchoalveolar lavage specimens: Analysis of sensitivity and specificity. *J. Clin. Microbiol.* 1997, 35, 830–835.
145. Gupta, R.; Mirdha, B.R.; Guleria, R.; Kumar, L.; Samantaray, J.C.; Agarwal, S.K.; Kabra, S.K.; Luthra, K. Diagnostic significance of nested polymerase chain reaction for sensitive detection of *Pneumocystis jirovecii* in respiratory clinical specimens. *Diagn. Microbiol. Infect. Dis.* 2009, 64, 381–388.
146. Flori, P.; Bellete, B.; Durand, F.; Raberin, H.; Cazorla, C.; Hafid, J.; Lucht, F.; Sung, R.T. Comparison between real-time PCR, conventional PCR and different staining techniques for diagnosing *Pneumocystis jiroveci* pneumonia from bronchoalveolar lavage specimens. *J. Med. Microbiol.* 2004, 53, 603–607.
147. Robberts, F.J.; Liebowitz, L.D.; Chalkley, L.J. Polymerase chain reaction detection of *Pneumocystis jiroveci*: Evaluation of 9 assays. *Diagn. Microbiol. Infect. Dis.* 2007, 58, 385–392.
148. Fujisawa, T.; Suda, T.; Matsuda, H.; Inui, N.; Nakamura, Y.; Sato, J.; Toyoshima, M.; Nakano, Y.; Yasuda, K.; Gemma, H.; et al. Real-time PCR is more specific than conventional PCR for induced sputum diagnosis of *Pneumocystis* pneumonia in immunocompromised patients without HIV infection. *Respirology* 2009, 14, 203–209.
149. Larsen, H.H.; Masur, H.; Kovacs, J.A.; Gill, V.J.; Silcott, V.A.; Kogulan, P.; Maenza, J.; Smith, M.; Lucey, D.R.; Fischer, S.H. Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing *Pneumocystis carinii* pneumonia. *J. Clin. Microbiol.* 2002, 40, 490–494.
150. Chumpitazi, B.F.; Flori, P.; Kern, J.B.; Brenier-Pinchart, M.P.; Hincky-Vitrat, V.; Brion, J.P.; Thiebaut-Bertrand, A.; Minet, C.; Maubon, D.; Pelloux, H. Characteristics and clinical relevance of the quantitative touch-down major surface glycoprotein polymerase chain reaction in the diagnosis of *Pneumocystis* pneumonia. *Med. Mycol.* 2011, 49, 704–713.
151. Alanio, A.; Desoubeaux, G.; Sarfati, C.; Hamane, S.; Bergeron, A.; Azoulay, E.; Molina, J.M.; Derouin, F.; Menotti, J. Real-time PCR assay-based strategy for differentiation between active *Pneumocystis jirovecii* pneumonia and colonization in immunocompromised patients. *Clin. Microbiol. Infect.* 2011, 17, 1531–1537.
152. Filliaux, J.; Malvy, S.; Alvarez, M.; Fabre, R.; Cassaing, S.; Marchou, B.; Linas, M.D.; Berry, A. Accuracy of a routine real-time PCR assay for the diagnosis of *Pneumocystis jirovecii* pneumonia. *J. Microbiol. Methods* 2008, 75, 258–261.
153. Rohner, P.; Jacomo, V.; Studer, R.; Schrenzel, J.; Graf, J.D. Detection of *Pneumocystis jirovecii* by two staining methods and two quantitative PCR assays. *Infection* 2009, 37, 261–265.
155. Dini, L.; du Plessis, M.; Frean, J.; Fernandez, V. High prevalence of dihydropteroate synthase mutations in *Pneumocystis jirovecii* isolated from patients with *Pneumocystis* pneumonia in South Africa. *J. Clin. Microbiol.* 2010, 48, 2016–2021.

156. Hauser, P.M.; Bille, J.; Lass-Florl, C.; Geltner, C.; Feldmesser, M.; Levi, M.; Patel, H.; Muggia, V.; Alexander, B.; Hughes, M.; et al. Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for *Pneumocystis jirovecii* infection by use of a commercial real-time PCR assay. *J. Clin. Microbiol.* 2011, 49, 1872–1878.

157. Alvarez-Martinez, M.J.; Miro, J.M.; Valls, M.E.; Moreno, A.; Rivas, P.V.; Sole, M.; Benito, N.; Domingo, P.; Munoz, C.; Rivera, E.; et al. Sensitivity and specificity of nested and real-time PCR for the detection of *Pneumocystis jiroveci* in clinical specimens. *Diagn. Microbiol. Infect. Dis.* 2006, 56, 153–160.

158. Gutierrez, S.; Morilla, R.; Leon, J.A.; Martin-Garrido, I.; Rivero, L.; Friaza, V.; Respaldiza, N.; Montes-Cano, M.A.; Teran, R.; de la Horra, C. High prevalence of *Pneumocystis jiroveci* colonization among young HIV-infected patients. *J. Adolesc. Health* 2011, 48, 103–105.

159. Iriart, X.; Witkowski, B.; Courtais, C.; Abbes, S.; Tkaczuk, J.; Courtade, M.; Cassaing, S.; Fillaux, J.; Blancher, A.; Magnaval, J.F.; et al. Cellular and cytokine changes in the alveolar environment among immunocompromised patients during *Pneumocystis jirovecii* infection. *Med. Mycol.* 2010, 48, 1075–1087.

160. Fitzpatrick, M.E.; Tedrow, J.R.; Hillenbrand, M.E.; Lucht, L.; Richards, T.; Norris, K.A.; Zhang, Y.; Sciurba, F.C.; Kaminski, N.; Morris, A. *Pneumocystis jirovecii* colonization is associated with enhanced Th1 inflammatory gene expression in lungs of humans with chronic obstructive pulmonary disease. *Microbiol. Immunol.* 2014, 58, 202–211.

161. Morris, A.; Wei, K.; Afshar, K.; Huang, L. Epidemiology and clinical significance of *Pneumocystis* colonization. *J. Infect. Dis.* 2008, 197, 10–17.

162. Morris, A.; Norris, K.A. Colonization by *Pneumocystis jirovecii* and its role in disease. *Clin. Microbiol. Rev.* 2012, 25, 297–317.

163. Desmet, S.; van Wijngaerden, E.; Maertens, J.; Verhaegen, J.; Verbeken, E.; de Munter, P.; Meersseman, W.; van Meensel, B.; van Eldere, J.; Lagrou, K. Serum (1–3)-β-D-glucan as a tool for diagnosis of *Pneumocystis jirovecii* pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. *J. Clin. Microbiol.* 2009, 47, 3871–3874.

164. Watanabe, T.; Yasuoka, A.; Tanuma, J.; Yazaki, H.; Honda, H.; Tsukada, K.; Honda, M.; Gatanaga, H.; Teruya, K.; Kikuchi, Y.; et al. Serum (1→3) β-D-glucan as a noninvasive adjunct marker for the diagnosis of *Pneumocystis* pneumonia in patients with AIDS. *Clin. Infect. Dis.* 2009, 49, 1128–1131.

165. Damiani, C.; Le Gal, S.; Lejeune, D.; Brahimi, N.; Virmaux, M.; Nevez, G.; Totet, A. Serum (1→3)-β-D-glucan levels in primary infection and pulmonary colonization with *Pneumocystis jirovecii*. *J. Clin. Microbiol.* 2011, 49, 2000–2002.

166. Damiani, C.; le Gal, S.; Da Costa, C.; Virmaux, M.; Nevez, G.; Totet, A. Combined quantification of pulmonary *Pneumocystis jirovecii* DNA and serum (1→3) β-D-glucan for differential diagnosis of *Pneumocystis* pneumonia and *Pneumocystis* colonization. *J. Clin. Microbiol.* 2013, 51, 3380–3388.
167. Held, J.; Koch, M.S.; Reischl, U.; Danner, T.; Serr, A. Serum (1→3)-β-D-glucan measurement as an early indicator of *Pneumocystis jirovecii* pneumonia and evaluation of its prognostic value. *Clin. Microbiol. Infect.* **2011**, *17*, 595–602.

168. Matsumoto, Y.; Matsuda, S.; Tegoshi, T. Yeast glucan in the cyst wall of *Pneumocystis carinii*. *J. Protozool.* **1989**, *36*, 21S–22S.

169. Finkelman, M.A. *Pneumocystis jirovecii* infection: Cell wall (1–3)-β-D-glucan biology and diagnostic utility. *Crit. Rev. Microbiol.* **2010**, *36*, 271–281.

170. Mennink-Kersten, M.A.; Ruegebrink, D.; Verweij, P.E. Pseudomonas aeruginosa as a cause of 1,3-β-D-glucan assay reactivity. *Clin. Infect. Dis.* **2008**, *46*, 1930–1931.

171. Sulahian, A.; Touratier, S.; Ribaud, P. False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. *N. Engl. J. Med.* **2003**, *349*, 2366–2367.

172. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-infected adults and adolescents. Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available online: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5804a1.htm (accessed on 7 September 2015).

173. EBPG Expert Group on Renal Transplantation. European Best Practice Guidelines for Renal Transplantation. Section IV: Long-term management of the transplant recipient. IV.7.1 Late infections. *Pneumocystis carinii* pneumonia. *Nephrol. Dial. Transplant.* **2002**, *17*, 36–39.

174. Kasiske, B.L.; Zeier, M.G.; Chapman, J.R.; Craig, J.C.; Ekberg, H.; Garvey, C.A.; Green, M.D.; Jha, V.; Josephson, M.A.; Kiberd, B.A.; et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: A summary. *Kidney Int.* **2010**, *77*, 299–311.

175. Higgins, R.M.; Bloom, S.L.; Hopkin, J.M.; Morris, P.J. The risks and benefits of low-dose cotrimoxazole prophylaxis for *Pneumocystis* pneumonia in renal transplantation. *Transplantation* **1989**, *47*, 558–560.

176. Chapman, J.R.; Marriott, D.J.; Chen, S.C.; Macdonald, P.S. Post-transplant *Pneumocystis jirovecii* pneumonia: A re-emerged public health problem? *Kidney Int.* **2013**, *84*, 240–243.

177. Masur, H.; Kaplan, J.E.; Holmes, K.K. Guidelines for preventing opportunistic infections among HIV-infected persons 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. *Ann. Intern. Med.* **2002**, *137*, 435–478.

178. Overgaard, U.M.; Helweg-Larsen, J. *Pneumocystis jiroveci* pneumonia (PCP) in HIV-1-negative patients: A retrospective study 2002–2004. *Scand. J. Infect. Dis.* **2007**, *39*, 589–595.

179. Ioannidis, J.P.; Cappelleri, J.C.; Skolnik, P.R.; Lau, J.; Sacks, H.S. A meta-analysis of the relative efficacy and toxicity of *Pneumocystis carinii* prophylactic regimens. *Arch. Intern. Med.* **1996**, *156*, 177–188.

180. Torre-Cisneros, J.; de la Mata, M.; Pozo, J.C.; Serrano, P.; Briceno, J.; Solorzano, G.; Mino, G.; Pera, C.; Sanchez-Guijo, P. Randomized trial of weekly sulfadoxine/pyrimethamine vs. daily low-dose trimethoprim-sulfamethoxazole for the prophylaxis of *Pneumocystis carinii* pneumonia after liver transplantation. *Clin. Infect. Dis.* **1999**, *29*, 771–774.
181. Stern, A.; Green, H.; Paul, M.; Vidal, L.; Leibovici, L. Prophylaxis for *Pneumocystis* pneumonia (PCP) in non-HIV immunocompromised patients. *Cochrane Database Syst. Rev.* 2014, doi:10.1002/14651858.CD005590.pub3.

182. Hughes, W.T. Use of dapsone in the prevention and treatment of *Pneumocystis carinii* pneumonia: A review. *Clin. Infect. Dis.* 1998, 27, 191–204.

183. Mohle-Boetani, J.; Akula, S.K.; Holodniy, M.; Katzenstein, D.; Garcia, G. The sulfone syndrome in a patient receiving dapsone prophylaxis for *Pneumocystis carinii* pneumonia. *West. J. Med.* 1992, 156, 303–306.

184. Lee, I.; Barton, T.D.; Goral, S.; Doyle, A.M.; Bloom, R.D.; Chojnowski, D.; Korenda, K.; Blumberg, E.A. Complications related to dapsone use for *Pneumocystis jirovecii* pneumonia prophylaxis in solid organ transplant recipients. *Am. J. Transplant.* 2005, 5, 2791–2795.

185. El-Sadr, W.M.; Murphy, R.L.; Yurik, T.M.; Luskin-Hawk, R.; Cheung, T.W.; Balfour, H.H., Jr.; Eng, R.; Hooton, T.M.; Kerkering, T.M.; Schutz, M.; et al. Atovaquone compared with dapsone for the prevention of *Pneumocystis carinii* pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. *N. Engl. J. Med.* 1998, 339, 1889–1895.

186. Gabardi, S.; Millen, P.; Hurwitz, S.; Martin, S.; Roberts, K.; Chandraker, A. Atovaquone versus trimethoprim-sulfamethoxazole as *Pneumocystis jirovecii* pneumonia prophylaxis following renal transplantation. *Clin. Transplant.* 2012, 26, E184–E190.

187. Baggish, A.L.; Hill, D.R. Antiparasitic agent atovaquone. *Antimicrob. Agents Chemother.* 2002, 46, 1163–1173.

188. Saukkonen, K.; Garland, R.; Koziel, H. Aerosolized pentamidine as alternative primary prophylaxis against *Pneumocystis carinii* pneumonia in adult hepatic and renal transplant recipients. *Chest* 1996, 109, 1250–1255.

189. Vasconcelles, M.J.; Bernardo, M.V.; King, C.; Weller, E.A.; Antin, J.H. Aerosolized pentamidine as *Pneumocystis* prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. *Biol. Blood Marrow Transplant.* 2000, 6, 35–43.

190. Hardy, W.D.; Northfelt, D.W.; Drake, T.A. Fatal, disseminated pneumocystosis in a patient with acquired immunodeficiency syndrome receiving prophylactic aerosolized pentamidine. *Am. J. Med.* 1989, 87, 329–331.

191. Zavascki, A.P.; Maia, A.L.; Goldani, L.Z. *Pneumocystis jiroveci* thyroiditis: Report of 15 cases in the literature. *Mycoses* 2007, 50, 443–446.

192. Sepkowitz, K.A.; Telzak, E.E.; Gold, J.W.; Bernard, E.M.; Blum, S.; Carrow, M.; Dickmeyer, M.; Armstrong, D. Pneumothorax in AIDS. *Ann. Intern. Med.* 1991, 114, 455–459.

193. Jules-Elysee, K.M.; Stover, D.E.; Zaman, M.B.; Bernard, E.M.; White, D.A. Aerosolized pentamidine: Effect on diagnosis and presentation of *Pneumocystis carinii* pneumonia. *Ann. Intern. Med.* 1990, 112, 750–757.

194. Siegel, J.D.; Rhinehart, E.; Jackson, M.; Chiarello, L. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. *Am. J. Infect. Control* 2007, 35, S65–S164.
195. Kaplan, J.E.; Benson, C.; Holmes, K.K.; Brooks, J.T.; Pau, A.; Masur, H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. *MMWR Recomm. Rep.* 2009, 58, 1–207.

196. Carmona, E.M.; Limper, A.H. Update on the diagnosis and treatment of *Pneumocystis* pneumonia. *Ther. Adv. Respir. Dis.* 2011, 5, 41–59.

197. Briel, M.; Bucher, H.C.; Bosacci, R.; Furrer, H. Adjunctive corticosteroids for *Pneumocystis jiroveci* pneumonia in patients with HIV-infection. *Cochrane Database Syst Rev.* 2006, doi:10.1002/14651858.CD006150.

198. Navin, T.R.; Beard, C.B.; Huang, L.; del Rio, C.; Lee, S.; Pieniazek, N.J.; Carter, J.L.; Le, T.; Hightower, A.; Rimland, D. Effect of mutations in *Pneumocystis carinii* dihydropteroate synthase gene on outcome of *P. carinii* pneumonia in patients with HIV-1: A prospective study. *Lancet* 2001, 358, 545–549.

199. Crothers, K.; Beard, C.B.; Turner, J.; Groner, G.; Fox, M.; Morris, A.; Eiser, S.; Huang, L. Severity and outcome of HIV-associated *Pneumocystis* pneumonia containing *Pneumocystis jiroveci* dihydropteroate synthase gene mutations. *AIDS* 2005, 19, 801–805.

200. Wharton, J.M.; Coleman, D.L.; Wofsy, C.B.; Luce, J.M.; Blumenfeld, W.; Hadley, W.K.; Ingram-Drake, L.; Volberding, P.A.; Hopewell, P.C. Trimethoprim-sulfamethoxazole or pentamidine for *Pneumocystis carinii* pneumonia in the acquired immunodeficiency syndrome: A prospective randomized trial. *Ann. Intern. Med.* 1986, 105, 37–44.

201. Sattler, F.R.; Cowan, R.; Nielsen, D.M.; Ruskin, J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of *Pneumocystis carinii* pneumonia in the acquired immunodeficiency syndrome: A prospective, noncrossover study. *Ann. Intern. Med.* 1988, 109, 280–287.

202. Klein, N.C.; Duncanson, F.P.; Lenox, T.H.; Forzsziapiak, C.; Sherer, C.B.; Quintzel, H.; Nunez, M.; Suarez, M.; Kawwaft, O.; Pitta-Alvarez, A.; et al. Trimethoprim-sulfamethoxazole versus pentamidine for *Pneumocystis carinii* pneumonia in AIDS patients: Results of a large prospective randomized treatment trial. *AIDS* 1992, 6, 301–305.

203. O’Brien, J.G.; Dong, B.J.; Coleman, R.L.; Gee, L.; Balano, K.B. A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who were receiving intravenous pentamidine therapy for *Pneumocystis carinii* pneumonia. *Clin. Infect. Dis.* 1997, 24, 854–859.

204. Benfield, T.; Atzori, C.; Miller, R.F.; Helweg-Larsen, J. Second-line salvage treatment of AIDS-associated *Pneumocystis jirovecii* pneumonia: A case series and systematic review. *J. Acquir. Immum. Defic. Syndr.* 2008, 48, 63–67.

205. Kim, T.; Hong, H.L.; Lee, Y.M.; Sung, H.; Kim, S.H.; Choi, S.H.; Kim, Y.S.; Woo, J.H.; Lee, S.O. Is caspofungin really an effective treatment for *Pneumocystis jirovecii* pneumonia in immunocompromised patients without human immunodeficiency virus infection? Experiences at a single center and a literature review. *Scand. J. Infect. Dis.* 2013, 45, 484–488.

206. Fishman, J.A. Treatment of infection due to *Pneumocystis carinii*. *Antimicrob. Agents Chemother.* 1998, 42, 1309–1314.
207. McKinnell, J.A.; Cannella, A.P.; Injean, P.; Gregson, A. Adjunctive glucocorticoid therapy for non-HIV-related *Pneumocystis carinii* pneumonia (NH-PCP). *Am. J. Transplant.* 2014, 14, 982–983.

208. Martin, S.I. Muted, but not mute. *Am. J. Transplant.* 2014, 14, 984.

209. Delclaux, C.; Zahar, J.R.; Amraoui, G.; Leleu, G.; Lebargy, F.; Brochard, L.; Schlemmer, B.; Brun-Buisson, C. Corticosteroids as adjunctive therapy for severe *Pneumocystis carinii* pneumonia in non-human immunodeficiency virus-infected patients: Retrospective study of 31 patients. *Clin. Infect. Dis.* 1999, 29, 670–672.

210. Moon, S.M.; Kim, T.; Sung, H.; Kim, M.N.; Kim, S.H.; Choi, S.H.; Jeong, J.Y.; Woo, J.H.; Kim, Y.S.; Lee, S.O. Outcomes of moderate-to-severe *Pneumocystis* pneumonia treated with adjunctive steroid in non-HIV-infected patients. *Antimicrob. Agents Chemother.* 2011, 55, 4613–4618.

211. Lemiale, V.; Debrumetz, A.; Delannoy, A.; Alberti, C.; Azoulay, E. Adjunctive steroid in HIV-negative patients with severe *Pneumocystis* pneumonia. *Respir Res.* 2013, 14, 87.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).